[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 173
1. Bortolin MT, Zanussi S, Talamini R, Simonelli C, Pratesi C, Tedeschi R, Abbruzzese L, Manuele R, Rupolo M, Tirelli U, De Paoli P: Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT). AIDS Res Hum Retroviruses; 2010 Feb;26(2):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT).
  • The kinetics and predictive value of HIV-1 DNA (HIV DNA) levels in relapsed or refractory HIV lymphoma patients, treated with high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT), were investigated.
  • HIV DNA was measured by real-time PCR in the peripheral blood mononuclear cells (PBMCs) of 22 patients observed for a median follow-up of 31.0 months.
  • At baseline, HIV DNA was found to be correlated with HIV-1 RNA (HIV RNA) (r = 0.56), but not with CD4(+) counts (r = -0.10).
  • HIV RNA load was under control for the entire follow-up, while HIV DNA levels were almost always detectable (baseline levels vs. 1 year from ASCT levels, p > 0.05).
  • Baseline HIV DNA levels were significantly different between alive and deceased patients (p = 0.03), and the overall survival (OS) analysis showed that for patients with higher HIV DNA levels at baseline there was a higher and nearly significant risk of death if compared to patients with lower levels (HR, 8.33, 95% CI, 0.99-70.06, p = 0.05).
  • Our study demonstrated that high HIV DNA levels at baseline could predict overall survival after ASCT in one of the largest cohorts of HIV lymphoma patients treated with salvage therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA, Viral / blood. HIV-1 / isolation & purification. Lymphoma, AIDS-Related / mortality. Stem Cell Transplantation. Viral Load


2. Ho SF, Fink C, Murray PI: Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma. Ocul Immunol Inflamm; 2005 Dec;13(6):471-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma.
  • We report an HIV-positive patient who developed a unilateral retinitis and subsequent intracranial lesions.
  • The finding of Epstein Barr virus (EBV) DNA at a > 1-log greater concentration in the vitreous compared to blood raised the possibility of a primary CNS non-Hodgkin's lymphoma, which was subsequently confirmed on brain biopsy.
  • [MeSH-major] DNA, Viral / genetics. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321894.001).
  • [ISSN] 0927-3948
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


3. Dispenzieri A, Gertz MA: Treatment of Castleman's disease. Curr Treat Options Oncol; 2005 May;6(3):255-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Castleman's disease.
  • Castleman's disease (CD) was first described in 1954 and further defined in 1956 by Castleman.
  • It responds well to surgical resection and is associated with a benign course.
  • Associated systemic symptoms are common.
  • There is an increased incidence of CD in patients with HIV.
  • The human herpes virus-8 is associated with nearly all of the HIV-associated CD cases and nearly 50% of non-HIV cases.
  • Interleukin (IL)-6 has also been shown to play a significant role in the pathogenesis of the disease.
  • Patients with CD are at increased risk for developing frank malignant lymphoma.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. HIV Infections / complications. Herpesvirus 8, Human / isolation & purification. Humans. Interleukin-6 / physiology. Lymphoma / complications

  • Genetic Alliance. consumer health - Castleman's Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999 Oct;10(10):1207-9 [10586338.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):429-35 [9517516.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2923-30 [1954381.001]
  • [Cites] Am J Dermatopathol. 1983 Jun;5(3):277-81 [6625119.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2496-506 [12456500.001]
  • [Cites] Acta Oncol. 2003;42(7):784-7 [14690166.001]
  • [Cites] Am J Hematol. 2004 Mar;75(3):176-7 [14978701.001]
  • [Cites] J Rheumatol. 1999 Jun;26(6):1400-3 [10381064.001]
  • [Cites] Eur J Haematol. 2003 Mar;70(3):181-2 [12605662.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1202-16 [4031967.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):119-26 [11835348.001]
  • [Cites] Eur J Pediatr. 1999 Aug;158(8):631-7 [10445341.001]
  • [Cites] Am J Clin Pathol. 1993 Oct;100(4):394-7 [8213634.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3643-53 [10339470.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]
  • [Cites] Am J Surg Pathol. 1990 Jul;14 (7):603-14 [2356921.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):602-5 [8302342.001]
  • [Cites] Ann Hematol. 1998 Oct;77(4):179-81 [9829851.001]
  • [Cites] Am J Hematol. 2003 May;73(1):48-53 [12701121.001]
  • [Cites] Clin Exp Dermatol. 2000 May;25(3):219-21 [10844500.001]
  • [Cites] Histopathology. 2001 Jun;38(6):510-8 [11422494.001]
  • [Cites] Am J Hematol. 1995 Aug;49(4):359-60 [7639289.001]
  • [Cites] Scand J Rheumatol. 1997;26(6):482-4 [9433413.001]
  • [Cites] Semin Diagn Pathol. 1988 Nov;5(4):346-64 [2464187.001]
  • [Cites] Hum Pathol. 1985 Feb;16(2):162-72 [2579015.001]
  • [Cites] AIDS. 1996 Jan;10(1):61-7 [8924253.001]
  • [Cites] Nephron. 1998;78(3):323-7 [9546694.001]
  • [Cites] J Am Acad Dermatol. 1991 Nov;25(5 Pt 2):955-9 [1761779.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Am J Nephrol. 1990;10(4):323-8 [2240060.001]
  • [Cites] Cancer. 1972 Mar;29(3):670-83 [4551306.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):525-31 [14975615.001]
  • [Cites] Clin Infect Dis. 2000 Aug;31(2):602-4 [10987728.001]
  • [Cites] Ann Intern Med. 1998 Apr 15;128(8):657-62 [9537940.001]
  • [Cites] Hematol Oncol. 1986 Jul-Sep;4(3):213-7 [3533746.001]
  • [Cites] Nephron. 2002 Mar;90(3):336-40 [11867955.001]
  • [Cites] Mod Pathol. 1996 Dec;9(12):1135-42 [8972472.001]
  • [Cites] Eur J Dermatol. 2002 Jul-Aug;12(4):355-9 [12095881.001]
  • [Cites] QJM. 2002 Apr;95(4):211-8 [11937647.001]
  • [Cites] Am J Surg Pathol. 1983 Apr;7(3):211-31 [6837832.001]
  • [Cites] Haematologica. 1984 Sep-Oct;69(5):556-67 [6437933.001]
  • [Cites] Nephron. 1993;65(4):628-32 [8302422.001]
  • [Cites] Blood. 1995 Aug 1;86(3):1131-8 [7620166.001]
  • [Cites] Clin Infect Dis. 2002 Oct 1;35(7):880-2 [12228826.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):333-5 [2355894.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3473-5 [11719390.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):545-7 [8615669.001]
  • [Cites] Br J Haematol. 1998 Dec;103(3):788-90 [9858232.001]
  • [Cites] Arch Pathol Lab Med. 1998 Nov;122(11):1026-9 [9822134.001]
  • [Cites] HIV Med. 2004 May;5(3):157-62 [15139981.001]
  • [Cites] Ann Oncol. 1992 Jan;3(1):85-6 [1606076.001]
  • [Cites] Am J Hematol. 1994 Jul;46(3):189-93 [7910717.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):706-17 [10091744.001]
  • [Cites] Cancer. 1956 Jul-Aug;9(4):822-30 [13356266.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2786-8 [12842986.001]
  • [Cites] J Pediatr Surg. 2003 Sep;38(9):E21-3 [14523880.001]
  • [Cites] Mod Pathol. 1992 Sep;5(5):525-30 [1285353.001]
  • [Cites] Am J Clin Pathol. 1978 Jan;69(1):86-90 [619617.001]
  • [Cites] Int J STD AIDS. 2003 Jan;14(1):61-2 [12590797.001]
  • [Cites] J Pediatr Surg. 2001 Dec;36(12):E22 [11733934.001]
  • [Cites] J Med Assoc Thai. 1997 Mar;80(3):195-201 [9175388.001]
  • [Cites] Am J Hematol. 2001 Feb;66(2):148-50 [11421297.001]
  • [Cites] Br J Haematol. 1995 Nov;91(3):668-70 [8555073.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):670-6 [11505414.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1365-72 [1873789.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3400-7 [15280195.001]
  • [Cites] J Intern Med. 1995 Jul;238(1):81-4 [7608651.001]
  • [Cites] Am J Kidney Dis. 2004 Jan;43(1):E3-9 [14712466.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1034-6 [12873182.001]
  • [Cites] Br J Dermatol. 1999 Feb;140(2):313-6 [10233229.001]
  • [Cites] Ann Oncol. 2000 Dec;11(12):1613-4 [11205472.001]
  • [Cites] Radiology. 1998 Nov;209(2):477-81 [9807577.001]
  • [Cites] Blood. 2000 Jan 1;95(1):56-61 [10607684.001]
  • [Cites] Haematologica. 1996 Jan-Feb;81(1):40-43 [8900850.001]
  • [Cites] Cancer Treat Rev. 1995 Jul;21(4):291-310 [7585657.001]
  • (PMID = 15869736.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-6
  • [Number-of-references] 78
  •  go-up   go-down


Advertisement
4. Jiang Y, Xu D, Zhao Y, Zhang L: Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma. PLoS One; 2008 Feb 06;3(2):e1569
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma.
  • BACKGROUND: Both Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are members of the human gamma herpesvirus family: each is associated with various human cancers.
  • The majority of AIDS-associated primary effusion lymphoma (PEL) are co-infected with both KSHV and EBV.
  • Our data about putative interactions between EBV and KSHV would be applicable to the majority of AIDS-associated PELs and may be relevant to the pathogenesis of PELs.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2003 Jun 5;310(2):199-206 [12781707.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Gen Virol. 2003 Aug;84(Pt 8):1941-9 [12867624.001]
  • [Cites] J Virol. 2003 Aug;77(16):8893-914 [12885907.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jun;82(12):4085-9 [2987963.001]
  • [Cites] EMBO J. 1986 Dec 1;5(12):3243-9 [3028777.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1652-6 [2830625.001]
  • [Cites] EMBO J. 1989 May;8(5):1447-53 [2548844.001]
  • [Cites] EMBO J. 1989 Jun;8(6):1819-26 [2548857.001]
  • [Cites] J Virol. 1990 Jan;64(1):313-21 [2152819.001]
  • [Cites] J Virol. 1990 Mar;64(3):1143-55 [2154599.001]
  • [Cites] J Virol. 1990 Mar;64(3):1227-32 [2154606.001]
  • [Cites] J Virol. 1990 Jun;64(6):2560-8 [2159531.001]
  • [Cites] J Virol. 1990 Aug;64(8):3753-9 [2164595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(23):9459-63 [2174563.001]
  • [Cites] J Virol. 2007 Jun;81(11):5788-806 [17392367.001]
  • [Cites] J Virol. 2007 Sep;81(17):9279-91 [17596302.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 [10591086.001]
  • [Cites] J Virol. 1993 Dec;67(12):7648-53 [8230484.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1929-38 [8114724.001]
  • [Cites] J Virol. 1994 May;68(5):3354-63 [8151794.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2748-59 [8654372.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] Infect Agents Dis. 1996 Oct;5(4):215-22 [8884366.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):31799-802 [8943219.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] J Virol. 2000 Feb;74(3):1061-8 [10627515.001]
  • [Cites] J Virol. 2000 Mar;74(6):2550-7 [10684269.001]
  • [Cites] Oncogene. 1991 Feb;6(2):195-204 [1847997.001]
  • [Cites] Genes Dev. 1991 Dec;5(12B):2441-54 [1661258.001]
  • [Cites] J Virol. 1992 Aug;66(8):5030-9 [1321285.001]
  • [Cites] J Virol. 1993 Aug;67(8):4651-8 [8392605.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1617-26 [10022850.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3216-23 [10082588.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Aug;73(8):6551-8 [10400751.001]
  • [Cites] J Virol. 1999 Sep;73(9):7271-7 [10438815.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Virol. 2005 Apr;79(8):4651-63 [15795251.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Jun;79(12):7453-65 [15919901.001]
  • [Cites] J Virol. 2005 Jul;79(13):8493-505 [15956592.001]
  • [Cites] J Virol. 2005 Nov;79(21):13298-309 [16227252.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] J Gen Virol. 2000 Dec;81(Pt 12):3043-8 [11086135.001]
  • [Cites] J Virol. 2000 Dec;74(24):11800-10 [11090180.001]
  • [Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]
  • [Cites] J Virol. 2001 Jan;75(1):341-50 [11119603.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(5):2388-99 [11160742.001]
  • [Cites] J Virol. 2001 Jul;75(13):6245-8 [11390631.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Virol. 2001 Oct;75(19):9446-57 [11533207.001]
  • [Cites] J Virol. 2001 Oct;75(19):9509-16 [11533213.001]
  • [Cites] J Virol. 2001 Nov;75(21):10334-47 [11581402.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] J Virol. 2001 Dec;75(24):12393-401 [11711629.001]
  • [Cites] J Virol. 2002 Feb;76(3):998-1003 [11773375.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6438-42 [11741976.001]
  • [Cites] Nat Med. 2002 Jun;8(6):594-9 [12042810.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Virology. 2002 Aug 1;299(2):301-14 [12202233.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] J Virol. 2003 Mar;77(6):3809-15 [12610155.001]
  • (PMID = 18253508.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108951; United States / NCRR NIH HHS / RR / RR15635; United States / NIAID NIH HHS / AI / R21 AI059132; United States / NCRR NIH HHS / RR / P20 RR015635; United States / NCI NIH HHS / CA / CA108951; United States / NIAID NIH HHS / AI / AI59132
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2215330
  •  go-up   go-down


5. Kim B, Jeon YK, Kim CW: Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease and kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case. J Korean Med Sci; 2009 Oct;24(5):970-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease and kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case.
  • Kaposi sarcoma herpes virus (KSHV), also known as human herpesvirus-8, plays an important role in the pathogenesis of Kaposi sarcoma (KS), multicentric Castleman disease (MCD) of the plasma cell type, and primary effusion lymphoma.
  • KSHV is rarely associated with the hemophagocytic syndrome (HPS), but when it does occur, it most occurs in immunocompromised patients.
  • We report herein an unusual case of KSHV-associated HPS in an immunocompetent patient.
  • This is the first case of multiple KSHV associated diseases including MCD and KS with KSHV-associated hemophagocytic syndrome in an HIV-negative, non-transplant, immunocompetent patient.
  • [MeSH-minor] Autopsy. HIV Seronegativity. Humans. Immunocompetence. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Virus associated hemophagocytic syndrome.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ky Med Assoc. 2000 Apr;98(4):161-5 [10816985.001]
  • [Cites] Intern Med. 2007;46(11):771-4 [17541233.001]
  • [Cites] AIDS. 2002 May 24;16(8):F9-18 [12004288.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):91-100 [12502931.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):285-91 [12856221.001]
  • [Cites] Autoimmun Rev. 2004 Feb;3(2):69-75 [15003190.001]
  • [Cites] J Clin Invest. 1990 Aug;86(2):592-9 [2384605.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):833-9 [8375854.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] Acta Oncol. 2004;43(8):698-704 [15764213.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]
  • [Cites] Isr Med Assoc J. 2006 Jul;8(7):489-93 [16889165.001]
  • [Cites] Eur J Haematol. 2007 Apr;78(4):361-4 [17331129.001]
  • [Cites] Pathol Int. 2001 Sep;51(9):671-9 [11696169.001]
  • (PMID = 19795003.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2752788
  • [Keywords] NOTNLM ; Giant Lymph Node Hyperplasia / Herpesvirus 8, Human / Lymphohistiocytosis, Hemophagocytic / Sarcoma, Kaposi
  •  go-up   go-down


6. Pantanowitz L, Kuperman M, Goulart RA: Clinical history of HIV infection may be misleading in cytopathology. Cytojournal; 2010;7:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical history of HIV infection may be misleading in cytopathology.
  • Human immunodeficiency virus (HIV)-infected patients are at an increased risk for developing opportunistic infections, reactive conditions and neoplasms.
  • As a result, a broad range of conditions are frequently included in the differential diagnosis of HIV-related lesions.
  • The clinical history of HIV infection may, however, be misleading in some cases.
  • Illustrative cases are presented in which knowledge of a patient's HIV status proved to be misleading and increased the degree of complexity of the cytologic evaluation.
  • Large atypical cells identified in his effusion were concerning for primary effusion lymphoma.
  • These cases demonstrate that knowledge of a patient's HIV status can be misleading in the evaluation of cytology specimens, with potential for misdiagnosis and/or multiple procedures.
  • To avoid this pitfall in the setting of HIV infection, common entities unrelated to HIV infection and artifacts should always be included in the differential diagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1989 Sep;96(3):460-6 [2766805.001]
  • [Cites] J HIV Ther. 2009 Jun;14(2):41-7 [19839366.001]
  • [Cites] Am J Surg Pathol. 1982 Dec;6(8):715-27 [6301296.001]
  • [Cites] Arch Pathol Lab Med. 1995 Sep;119(9):811-4 [7545386.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):425-31 [7726138.001]
  • [Cites] Pathol Res Pract. 1997;193(7):497-502 [9342756.001]
  • [Cites] Eur Respir J. 1997 Nov;10(11):2638-43 [9426107.001]
  • [Cites] Clin Chest Med. 1998 Jun;19(2):341-9 [9646985.001]
  • [Cites] Diagn Cytopathol. 1998 Dec;19(6):451-4 [9839136.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):656-61 [10366147.001]
  • [Cites] Diagn Cytopathol. 2000 Nov;23(5):322-5 [11074626.001]
  • [Cites] Diagn Cytopathol. 2004 Jun;30(6):381-5 [15176023.001]
  • [Cites] J Med Assoc Thai. 2004 Sep;87 Suppl 2:S152-60 [16083180.001]
  • [Cites] Ann Thorac Surg. 2006 Jun;81(6):2037-43 [16731126.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):469-78 [16894295.001]
  • [Cites] Cytopathology. 2008 Apr;19(2):86-93 [17916096.001]
  • [Cites] J Thorac Imaging. 2008 May;23(2):138-41 [18520574.001]
  • [Cites] Ear Nose Throat J. 2008 Jul;87(7):374-5 [18633927.001]
  • [Cites] Oncology. 2008;74(3-4):167-76 [18714165.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1209-15 [18808357.001]
  • [Cites] Diagn Cytopathol. 2009 May;37(5):353-4 [18973265.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):27-34 [19339937.001]
  • [Cites] AJR Am J Roentgenol. 1987 Jan;148(1):25-8 [3491519.001]
  • (PMID = 20607096.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2895884
  • [Keywords] NOTNLM ; AIDS / HIV / cytology / misleading
  •  go-up   go-down


7. Hongsakul K, Laothamatas J: Computer tomographic findings of the brain in HIV-patients at Ramathibodi Hospital. J Med Assoc Thai; 2008 Jun;91(6):895-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer tomographic findings of the brain in HIV-patients at Ramathibodi Hospital.
  • OBJECTIVE: To determine the underlying cause of the brain lesions in adult HIV patients referred for CT scan at Ramathibodi Hospital and to evaluate accuracy of CT for the diagnosis of the brain lesion.
  • MATERIAL AND METHOD: Data from first CT scan of the brain of 195 adult HIV patients at Ramathibodi Hospital were reviewed The final diagnoses from medical records were assessed followed by CSF analysis, pathological report, and therapeutic treatment.
  • RESULTS: One hundred ninety five adult seropositive patients for HIV underwent CT scan of the brain, 59% were HIV encephalopathy (HIVE), 22% toxoplasmosis, 9% cryptococcoma, 5% tuberculous meningitis, 4% tuberculoma, 3% progressive multifocal leukoencephalopathy (PML), 2% lymphoma, and 1% normal.
  • CONCLUSION: HIV encephalopathy was the most common finding of adult HIV brains.
  • Toxoplasmosis was the most common opportunistic parenchymal brain lesion in adult HIV brains.
  • CT was the modality of choice for diagnosis and exclusion of toxoplasmosis, but it cannot determine the cause of disease showing meningitis pattern.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Brain / physiopathology. Brain Diseases / diagnosis. HIV Infections / complications. Tomography, X-Ray Computed / instrumentation


8. Deffenbacher KE, Iqbal J, Liu Z, Fu K, Chan WC: Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr; 2010 May 1;54(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression.
  • HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.
  • Due to their aggressive nature, AIDS-related lymphomas (ARL) can also be more difficult to classify.
  • Genetic abnormalities are known to play a significant role in HIV(-) lymphomagenesis.
  • Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.
  • These data demonstrate the ability to molecularly classify B-ARL lymphomas by gene expression and identified DNA copy number alterations targeted in B-ARL.
  • [MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216076.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Gotoh M, Kitahara T, Iguchi T, Izumi M, Mukai K, Ohyashiki K: [HIV-related multiple non-Hodgkin lymphomas]. Rinsho Ketsueki; 2008 Nov;49(11):1552-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-related multiple non-Hodgkin lymphomas].
  • He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).
  • We diagnosed double lymphomas related to AIDS.
  • The patient received anti-retroviral therapy, and started the CHOP regimen for the double lymphomas, resulting in transient improvement.
  • Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.
  • This case suggested that cancer generation was promoted by low immunity, although it is known that ambivalent tumors such as non-Hodgkin lymphomas can occur frequently.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047787.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


10. Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T, Horie R: Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect; 2008 Jun;10(7):748-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) causes EBV-associated lymphoproliferative diseases in patients with profound immune suppression.
  • Most of these diseases are life-threatening and the prognosis of AIDS-associated lymphomas is extremely unfavorable.
  • We investigated the possibility of nuclear factor kappa B (NF-kappaB) inhibition by dehydroxymethylepoxyquinomicin (DHMEQ) for the treatment and prevention of EBV-associated lymphoproliferative diseases.
  • These results suggest that NF-kappaB is a molecular target for the treatment and prevention of EBV-associated lymphoproliferative diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538617.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / Immunologic Factors; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin
  •  go-up   go-down


11. Epeldegui M, Widney DP, Martínez-Maza O: Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol; 2006 Sep;18(5):444-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions.
  • PURPOSE OF REVIEW: We discuss recently published studies that elucidate the pathogenesis of AIDS-associated lymphoma.
  • RECENT FINDINGS: Several recent reports have provided valuable new information on the role of gamma-herpesviruses in the pathogenesis of AIDS-associated lymphoma.
  • In addition to this, significant new information has become available on how B cell activation-associated DNA-modifying events, involving activation-induced cytidine deaminase and DNA polymerase-eta, contribute to the molecular lesions that result in AIDS-associated lymphoma.
  • In particular, new evidence that oncogenic viruses can directly induce activation-induced cytidine deaminase expression and oncogene mutation in human B cells is of central relevance to better understanding the pathogenesis of AIDS-associated lymphoma.
  • SUMMARY: New information provides insights into the contributions of immune dysfunction and oncogenic virus infection to pathogenesis of AIDS-associated lymphoma, and may lead to new potential targets for therapeutic intervention in these cancers.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / virology. Lymphoma, B-Cell / genetics. Oncogenic Viruses / pathogenicity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894291.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI35040; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA70080; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.7 / DNA-Directed DNA Polymerase; EC 2.7.7.7 / Rad30 protein; EC 3.5.4.5 / Cytidine Deaminase
  • [Number-of-references] 28
  •  go-up   go-down


12. Tanaka PY, Calore EE: P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract; 2007;203(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
  • It still needs to be clarified whether P-gp expression has a significant impact on non-Hodgkin's lymphoma treatment response, but a poor outcome has been reported in patients with positive P-gp expression.
  • AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
  • In an attempt to determine a possible relationship between MDR and poor outcome in this population, histologic samples obtained from 45 non-Hodgkin's lymphoma HIV-infected patients without previous cytotoxic therapy were submitted to immunohistochemical analysis using monoclonal antibody C494 specific for the MDR-1 isoform of P-gp.
  • In patients having achieved complete remission, the median disease-free survival (DFS) was not reached; the mean DFS was 57.2 months with DFS rates of 72.9% in three years.
  • Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Res Pract. 2007;203(10):763
  • (PMID = 17157997.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF: Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med; 2005 Jan;6(1):21-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
  • BACKGROUND: Neurological disorders are common in HIV-infected patients.
  • Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.
  • OBJECTIVES: To investigate the clinical utility of flow cytometry immunophenotyping (FCI) in diagnosing or discarding leptomeningeal involvement in HIV-infected patients and to compare its sensitivity with that of conventional cytological methods.
  • METHODS: Fifty-six cerebrospinal fluid (CSF) samples from 29 HIV-infected patients were independently evaluated by flow cytometry and cytology.
  • RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.
  • This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670248.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Carbone A, Gloghini A, Vaccher E, Marchetti G, Gaidano G, Tirelli U: KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype. J Clin Pathol; 2005 Oct;58(10):1039-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype.
  • BACKGROUND: Kaposi sarcoma associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) associated lymphomas, which often develop in human immunodeficiency virus (HIV) infected patients with advanced AIDS, present predominantly as primary effusion lymphoma (PEL) or, less frequently, as "solid" extracavitary based lymphomas, associated with serous effusions.
  • These last lymphomas, also called "solid PEL", have been reported before the development of an effusion lymphoma and after resolution of PEL.
  • Interestingly, KSHV/HHV-8 associated lymphomas that present as solid or extracavitary based lesions in HIV seropositive patients without serous effusions have been reported recently.
  • METHODS/RESULTS: This paper provides evidence for the existence of a previously undescribed KSHV/HHV-8 associated lymphoma in HIV seronegative patients without serous effusions.
  • These lymphomas exhibit a predilection for the lymph nodes and display anaplastic large cell morphology.
  • B and T cell associated antigens and other commonly used lymphoid markers were absent or weakly demonstrable in a fraction of the tumour cells.
  • CONCLUSIONS: Analysis of viral infection and immunohistological studies are of primary importance to define this lymph node based KSHV/HHV-8 associated lymphoma with anaplastic large cell morphology and plasmablastic immunophenotype occurring in HIV seronegative patients without serous effusions.
  • [MeSH-major] Herpesviridae Infections / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma, Large B-Cell, Diffuse / virology
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. HIV Seronegativity. Humans. Immunophenotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] Leuk Lymphoma. 1999 Oct;35(3-4):379-87 [10706463.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):753-5 [10782162.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] AIDS Patient Care STDS. 2002 Apr;16(4):139-45 [12015867.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):630 [12827623.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] J Clin Virol. 2003 Oct;28(2):155-64 [12957185.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):693-7 [15105661.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Dec;8(4):293-312 [9620643.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Lab Invest. 1998 Dec;78(12):1637-42 [9881964.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):165-74 [10343068.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):992-4 [10435572.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Hum Pathol. 2002 Aug;33(8):846-9 [12203218.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1363-7 [12360052.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):831-44 [12525917.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] J Clin Pathol. 1994 May;47(5):418-22 [7517959.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):53-7 [8686762.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):318-23 [8759892.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Ann Intern Med. 1996 Nov 15;125(10):822-5 [8928989.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1198-201 [9129085.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] Int J Cancer. 1997 Oct 9;73(2):303-4 [9335459.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • (PMID = 16189148.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Other-IDs] NLM/ PMC1770735
  •  go-up   go-down


15. Heyns CF, Groeneveld AE, Sigarroa NB: Urologic complications of HIV and AIDS. Nat Clin Pract Urol; 2009 Jan;6(1):32-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urologic complications of HIV and AIDS.
  • In recent years the nature of HIV infection has been dramatically transformed from an invariably fatal disease to a chronic disorder with a relatively benign course.
  • Disease progression from HIV to AIDS and HIV-related mortality can be reduced effectively by several years of treatment with highly active antiretroviral therapy (HAART).
  • For patients who do not have access to HAART, HIV infection continues to be a lethal disorder characterized by opportunistic infection with uncommon organisms (e.g. mycobacteria, fungi, parasites and viruses), as well as lethal malignancies such as Kaposi sarcoma, non-Hodgkin lymphoma and squamous cell carcinoma of the penis or cervix.
  • In patients receiving HAART, urologic complications are likely to be caused by adverse effects of antiretroviral medication (e.g. indinavir urolithiasis) or disorders associated with aging, such as benign prostatic hyperplasia and prostate cancer.
  • Prospective clinical trials have shown that adult male circumcision can reduce the rate of female to male HIV transmission by more than 50%; however, the development of preventive or curative modalities with 100% efficacy remains elusive.
  • [MeSH-major] HIV Infections / complications. Urologic Diseases / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Nat Clin Pract Urol. 2010 Apr;7(4):178
  • (PMID = 19132004.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 134
  •  go-up   go-down


16. Ho-Yen C, Chang F, van der Walt J, Lucas S: Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature. Adv Anat Pathol; 2007 Nov;14(6):431-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature.
  • The gastrointestinal (GI) tract is a common internal organ to be involved by human immunodeficiency virus (HIV)-related malignancies.
  • It is the second most common site for Kaposi sarcoma after skin, and the commonest visceral site, for Kaposi sarcoma in AIDS patients.
  • GI lymphomas have been documented in approximately 25% of AIDS patients with systemic lymphomas.
  • Moreover, GI involvement of AIDS-lymphoma has been associated with poor prognosis and short survival.
  • Several other malignancies that occur in the GI tract are also closely related to HIV-infected or immunosuppressed individuals; these include posttransplant lymphoproliferative disorder, Epstein-Barr virus-associated smooth muscle tumors, anal precancerous lesions, and squamous cell carcinoma.
  • As a result of active antiretroviral therapy, patients infected with HIV are living longer and are consequently at increased risk for development of cancer.
  • Therefore, it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors may change in the future.
  • In this paper, the clinicopathologic features of GI malignancies associated with AIDS patients are reviewed and the differential diagnosis with other mimic lesions is discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Gastrointestinal Neoplasms / pathology. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / pathology. Sarcoma, Kaposi / pathology


17. Epeldegui M, Vendrame E, Martínez-Maza O: HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res; 2010 Dec;48(1-3):72-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.
  • HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL).
  • The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein-Barr virus-infected B cells, as well as HIV infection-associated immune dysregulation, including chronic B-cell activation.
  • In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in HIV-infected individuals.
  • [MeSH-major] AIDS-Related Opportunistic Infections / immunology. Acquired Immunodeficiency Syndrome / immunology. B-Lymphocytes / immunology. Epstein-Barr Virus Infections / immunology. HIV / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology


18. Kelemen K, Cao W, Peterson LC, Evens AM, Variakojis D: Primary mediastinal large B-cell lymphoma in HIV: report of two cases. J Hematop; 2009 Mar;2(1):45-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma in HIV: report of two cases.
  • Primary mediastinal large B cell lymphoma (PMLBCL) is a subtype of diffuse large B cell lymphoma arising in the mediastinum with distinctive clinical and morphological features.
  • Though diffuse large B cell lymphoma is one of the most common non-Hodgkin lymphoma associated with AIDS, there are no data available regarding the association of HIV and PMLBCL.
  • We report here two cases of PMLBCL arising in AIDS patients.
  • One of the two patients, a 25-year-old woman who had localized disease and evidence of Epstein-Barr virus in lymphoma cells, did not respond to chemotherapy and died of disease progression 5 months after diagnosis.
  • The second patient, a 38-year-old male with disseminated disease, responded to therapy and is disease-free after 9 months of follow-up.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):44-54 [8465656.001]
  • [Cites] J Pathol. 1992 Aug;167(4):381-4 [1328576.001]
  • [Cites] Blood. 1991 Aug 1;78(3):780-8 [1713514.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Blood. 2007 Aug 1;110(3):972-8 [17400912.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Am J Med Sci. 2005 Mar;329(3):136-8 [15767818.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):1135-48 [8880201.001]
  • [Cites] Br J Haematol. 1995 Jun;90(2):235-43 [7794745.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 19669223.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2713493
  •  go-up   go-down


19. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA: Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol; 2006 Feb;54(2):189-206; quiz 207-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignancy and human immunodeficiency virus disease.
  • Certain skin cancers occur with increased frequency or altered course in patients infected with HIV.
  • Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV.
  • The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy.
  • Cutaneous T-cell lymphoma (CTCL) is rare in this population.
  • Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.
  • LEARNING OBJECTIVE: At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with HIV.
  • [MeSH-major] HIV Infections / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443048.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 274
  •  go-up   go-down


20. Nagajothi N, Dham SK, Gelfand Y, Sanmugarajah J: Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy. J Natl Med Assoc; 2007 Jul;99(7):799-801
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy.
  • Anaplastic large-cell lymphoma (ALCL) has rarely been described in patients with acquired immunodeficiency syndrome (AIDS).
  • Reports of treatment of ALCL in the setting of AIDS are rare as well.
  • Dose-adjusted EPOCH (DA-EPOCH; etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) has been shown to be well tolerated and effective in the treatment of AIDS-related aggressive B-cell lymphomas.
  • Treatment of AIDS-associated ALCL with DA-EPOCH has not been reported.
  • This report describes two patients with AIDS-associated ALCL treated with DA-EPOCH chemotherapy.
  • Both patients presented with advanced disease.
  • She had an excellent response with rapid improvement of cutaneous disease and lymphadenopathy starting three days after the first cycle.
  • Our experience suggests that DA-EPOCH is an effective treatment for AIDS-associated ALCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1694-700 [7655001.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3078-90 [8221575.001]
  • [Cites] Am J Surg Pathol. 1988 Apr;12(4):264-74 [3354752.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Ai Zheng. 2004 Aug;23(8):943-6 [15301720.001]
  • (PMID = 17668647.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  • [Other-IDs] NLM/ PMC2574342
  •  go-up   go-down


21. Vaghefi P, Martin A, Prévot S, Charlotte F, Camilleri-Broët S, Barli E, Davi F, Gabarre J, Raphael M, Poirel HA: Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status. AIDS; 2006 Nov 28;20(18):2285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status.
  • BACKGROUND: The pathologic heterogeneity of AIDS related lymphomas (ARL) reflects several pathogenic mechanisms: chronic antigenic stimulation, Epstein-Barr virus (EBV) infection, and genomic abnormalities.
  • Genetic abnormalities, known to play a major role in lymphomas of non-immunocompromised patients, are not well characterized in ARL.
  • DNA-CNC tended to be more frequent in EBV-positive lymphomas with latency type II/III than in EBV-positive latency I or EBV-negative lymphomas.
  • Most chromosomal regions affected in HIV-related lymphoma were similar to those already reported in HIV-negative lymphomas.
  • The results suggested an inverse relationship between EBV infection (latency II/III), associated with deep acquired immune suppression, and the number of chromosomal alterations which may be explained by a direct role of viral proteins in lymphomagenesis by activation of signalling pathways without needing several genomic alterations.
  • [MeSH-major] Epstein-Barr Virus Infections / genetics. Lymphoma, AIDS-Related / genetics
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / complications. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Chromosome Aberrations. Chromosomes, Human / genetics. Clone Cells / immunology. DNA, Viral / genetics. Female. Genes, Viral / genetics. Genes, Viral / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / immunology. Male. Middle Aged. Nucleic Acid Hybridization / methods

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117014.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


22. Corti M, de Dios Soler M, Bare P, Villafañe MF, De Tezanos Pinto M, Perez Bianco R, Narbaitz M: [AIDS related lymphomas: Histopathological subtypes and association with Epstein Barr virus and Human Herpes virus type-8]. Medicina (B Aires); 2010;70(2):151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS related lymphomas: Histopathological subtypes and association with Epstein Barr virus and Human Herpes virus type-8].
  • [Transliterated title] Linfomas asociados con la infección por el virus de la inmunodeficiencia humana: subtipos histológicos y asociación con los virus de Epstein Barr y Herpes-8.
  • Non-Hodgkin lymphomas (NHL) of the B-cell type are the second most common neoplasm among patients with human immunodeficiency virus (HIV) infection and AIDS.
  • Here, we evaluated 48 cases of AIDS-related lymphomas (ARL) diagnosed at the Histopathological Division of the Instituto de Investigaciones Hematológicas of the National Academy of Medicine.
  • Additionally, biotinilated oligonucleotides were used to determine the presence of DNA of the Human Herpes virus type-8 (HHV-8) in 14/14 biopsy smears corresponding to plasmablastic lymphomas (PL).
  • All were fenotype B cell lymphomas with an aggressive course and advanced neoplasm disease at the time of diagnosis.
  • Virological findings showed the strong association between EBV and AIDS-related NHL.
  • According to the histopathological subtype, the EBV genome was detected in 16/21 (76%) diffuse large B cell lymphomas, 1/3 Burkitt lymphoma and 3/4 (75%) of primary central nervous system lymphomas.
  • Hodgkin lymphoma were more frequent in males 18/20 (90%), with an aggressive clinical course and a significant predominance of the subtypes associated with worse prognosis (90% of cases).
  • We consider that all cases of AIDS related lymphomas should be assessed for the presence of EBV because its presence may play a role in the prognosis.
  • [MeSH-major] DNA, Viral / analysis. Herpesvirus 4, Human / genetics. Hodgkin Disease / virology. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447898.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


23. Panarelli NC, Furman RR, Wang YL, Elstrom R, Cohen JA, Chadburn A: NK/T cell non-Hodgkin lymphoma in a HIV-positive patient. J Hematop; 2010;3(1):35-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK/T cell non-Hodgkin lymphoma in a HIV-positive patient.
  • NK/T lymphomas have rarely been reported in HIV/AIDS patients.
  • Here we report a case of a 37-year-old woman, with AIDS and a recent diagnosis of Kaposi sarcoma in a mesenteric lymph node, who presented with extra-ocular nerve palsies and gastrointestinal bleeding.
  • A small intestine resection specimen revealed an extra-nodal NK/T cell lymphoma, nasal type.
  • The unique presentation of this rare and aggressive lymphoma in the setting of AIDS and Kaposi sarcoma underscores the importance of maintaining a broad differential diagnosis when evaluating a malignant neoplasm from a HIV-positive patient.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):480-3 [15239400.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):738-41 [12033970.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1356-64 [19041057.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):881-6 [17509985.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):304-9 [10656746.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):660-2 [11300939.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):326-8 [11452946.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3931-7 [19029440.001]
  • [Cites] Neuropathology. 2007 Aug;27(4):396-402 [17899696.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] J Assoc Physicians India. 2006 Nov;54:890-2 [17249261.001]
  • (PMID = 21373175.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2883910
  • [Keywords] NOTNLM ; AIDS / HIV / Kaposi sarcoma / Natural killer/T cell lymphoma
  •  go-up   go-down


24. Osorio S G, Montenegro U C: [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review]. Rev Chilena Infectol; 2007 Apr;24(2):117-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review].
  • [Transliterated title] Linfomas asociados a infección por virus de inmunodeficiencia humana en un complejo hospitalario de la Región Metropolitana, Chile: 1990-2002. Reporte de 14 casos y revisión.
  • The association of HIV infection and lymphoma in patients attending at the South Health Metropolitan Reference Centre is presented.
  • RESULTS: 14 cases were detected, 10 non Hodgkin lymphoma patients (7 with high malignancy and 50% in stages III-IVB) and 4 with Hodgkin lymphoma (3 with mixed cellularity, 2 in stage IVB).
  • Ten patients were classified under stage C3 of AIDS CDC criteria, the mean CD4 count was 139 cells/mm3 and mean CV was 5,32 log.
  • Eighty six percent of patients presented with unique or multiples lymphonodes, with predominance of advanced lymphoma stage.
  • Conventional CHOP chemotherapy was the treatment for high risk and extended non Hodgkin lymphomas and for extended Hodgkin lymphomas the ABVD protocol was administered.
  • Global mortality in this series was 71%, attributable to tumor disease per se or to sepsis.
  • Four patients survived (18 to 50 months) in complete remission, 2 non Hodgkin lymphomas and 2 Hodgkin lymphomas.
  • The low incidence of lymphoma and AIDS association and the high frequency of lymphomas with localized or generalized lymphonodes in this series are remarkable.
  • [MeSH-major] Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Chile / epidemiology. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453069.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 30
  •  go-up   go-down


25. Benicchi T, Ghidini C, Re A, Cattaneo C, Casari S, Caimi L, Rossi G, Imberti L: T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation; 2005 Sep 15;80(5):673-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma.
  • BACKGROUND: One of the major concern for high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT) for HIV-associated lymphoma is that posttransplant immunosuppression might worsen immune defects of HIV individuals.
  • Since the introduction of highly active antiretroviral therapy has made HSCT possible also in these patients, we analyzed whether the immune system already compromised by HIV infection might support an efficient T-cell recovery after HSCT.
  • METHODS: The kinetics and the extent of T-cell reconstitution were investigated before and after HSCT in four patients with HIV-related lymphoma (one with Hodgkin's Disease and three with non-Hodgkin's lymphoma) by measuring the thymic output, the level of IL-7 and the heterogeneity of T-cell repertoire.
  • CONCLUSIONS: High-dose therapy and HSCT in HIV patients under highly active antiretroviral therapy does not worsen the immune defects.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / therapy


26. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups: Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol; 2008 Feb;140(4):411-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
  • Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma.
  • This phase II trial aimed to evaluate the safety and efficacy of six cycles of R-CHOP in patients with HIV-related DLBCL and to determine whether response to highly active antiretroviral therapy (HAART) had prognostic impact.
  • Complete response was achieved in 55 (69%) patients, with an estimated 3-year disease-free survival of 77% and 3-year overall survival of 56%.
  • In HIV-related DLBCL R-CHOP is feasible, safe and effective.
  • The prognosis depends on lymphoma-related parameters and on the response to HAART.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162120.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


27. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA: RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med; 2010 Jun 16;2(36):36ra43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.
  • AIDS patients who develop lymphoma are often treated with transplanted hematopoietic progenitor cells.
  • As a first step in developing a hematopoietic cell-based gene therapy treatment, four patients undergoing treatment with these transplanted cells were also given gene-modified peripheral blood-derived (CD34(+)) hematopoietic progenitor cells expressing three RNA-based anti-HIV moieties (tat/rev short hairpin RNA, TAR decoy, and CCR5 ribozyme).
  • In vitro estimates of successful expression of the anti-HIV moieties were initially as high as 22% but declined to approximately 1% over 4 weeks of culture.
  • Transfected cells were successfully engrafted in all four infused patients by day 11, and there were no unexpected infusion-related toxicities.
  • These results support the development of an RNA-based cell therapy platform for HIV.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]
  • [Cites] Mol Ther. 2007 Jun;15(6):1182-8 [17406343.001]
  • [Cites] Hum Gene Ther. 2008 Jun;19(6):622-34 [18533892.001]
  • [Cites] J Gene Med. 2008 Oct;10(10):1059-70 [18642399.001]
  • [Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]
  • [Cites] Science. 2009 Mar 6;323(5919):1304-7 [19265012.001]
  • [Cites] Mol Ther. 2009 May;17(5):844-50 [19259065.001]
  • [Cites] Science. 2009 Nov 6;326(5954):818-23 [19892975.001]
  • [Cites] Gene Ther. 2010 Mar;17(3):389-99 [19865182.001]
  • [Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]
  • [Cites] Mol Ther. 2002 Apr;5(4):479-84 [11945076.001]
  • [Cites] Gene Ther. 2002 Aug;9(16):1055-64 [12140733.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1730-4 [12457288.001]
  • [Cites] Mol Ther. 2003 Mar;7(3):325-33 [12668128.001]
  • [Cites] Mol Ther. 2003 Jul;8(1):62-71 [12842429.001]
  • [Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]
  • [Cites] Blood. 2004 Feb 1;103(3):796-803 [12920024.001]
  • [Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]
  • [Cites] J Gene Med. 2004 Mar;6(3):268-77 [15026988.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):395-6 [3166513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9870-4 [1409715.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Jul 15;84(2):421-32 [7517715.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4618-28 [8639830.001]
  • [Cites] Gene Ther. 1996 Aug;3(8):717-24 [8854097.001]
  • [Cites] J Virol. 1997 Jun;71(6):4707-16 [9151864.001]
  • [Cites] J Virol. 1999 May;73(5):3649-60 [10196257.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] Clin Immunol. 2005 Apr;115(1):26-32 [15870017.001]
  • [Cites] Mol Ther. 2005 Jul;12(1):77-86 [15963923.001]
  • [Cites] Mol Ther. 2005 Oct;12(4):697-706 [16039909.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):900-9 [16115802.001]
  • [Cites] Mol Ther. 2006 Feb;13(2):366-73 [16325473.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1751-60 [16269617.001]
  • [Cites] Clin Infect Dis. 2006 Apr 1;42(7):1003-10 [16511767.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3305-12 [16857988.001]
  • [Cites] Mol Ther. 2007 May;15(5):1024-33 [17356541.001]
  • [Cites] Methods Mol Biol. 2008;434:99-112 [18470641.001]
  • (PMID = 20555022.001).
  • [ISSN] 1946-6242
  • [Journal-full-title] Science translational medicine
  • [ISO-abbreviation] Sci Transl Med
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043-49; United States / NIAID NIH HHS / AI / AI61839; United States / NHLBI NIH HHS / HL / R01 HL074704; United States / NIAID NIH HHS / AI / AI42552; United States / NCI NIH HHS / CA / CA107399-05; United States / NIAID NIH HHS / AI / P01 AI061839-04; United States / NIAID NIH HHS / AI / R37 AI029329; United States / NCRR NIH HHS / RR / RR000043-49; United States / NIAID NIH HHS / AI / AI061839-04; United States / NHLBI NIH HHS / HL / HL07470; United States / NCI NIH HHS / CA / P50 CA107399-05; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCRR NIH HHS / RR / RR025083-01; United States / NCI NIH HHS / CA / P30 CA33572-26; United States / NCRR NIH HHS / RR / S10 RR025083-01; United States / NIAID NIH HHS / AI / AI042552-11; United States / NCI NIH HHS / CA / P30 CA033572-29; United States / NCRR NIH HHS / RR / M01 RR000043; United States / NHLBI NIH HHS / HL / R01 HL074704-07; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NCI NIH HHS / CA / P30 CA033572; United States / NIAID NIH HHS / AI / R01 AI042552; United States / NCRR NIH HHS / RR / S10 RR025083; United States / NIAID NIH HHS / AI / R01 AI042552-11; United States / NCRR NIH HHS / RR / S10RR025083-01; United States / NHLBI NIH HHS / HL / HL074704-07; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA
  • [Other-IDs] NLM/ NIHMS305014; NLM/ PMC3130552
  •  go-up   go-down


28. Sathekge M, Goethals I, Maes A, van de Wiele C: Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Mol Imaging; 2009 Jul;36(7):1176-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography in patients suffering from HIV-1 infection.
  • This paper reviews currently available PET studies performed either to improve our understanding of the pathogenesis of HIV-1 infection or to assess the value of PET imaging in the clinical decision making of patients infected with HIV-1 presenting with AIDS-related opportunistic infections and malignancies.
  • FDG PET has shown that HIV-1 infection progresses by distinct anatomical steps, with involvement of the upper torso preceding involvement of the lower part of the torso, and that the degree of FDG uptake relates to viral load.
  • The former finding suggests that lymphoid tissues are engaged in a predictable sequence and that diffusible mediators of activation might be important targets for vaccine or therapeutic intervention strategies.
  • In lipodystrophic HIV-infected patients, limited available data support the hypothesis that stavudine-related lipodystrophy is associated with increased glucose uptake by adipose tissue as a result of the metabolic stress of adipose tissue in response to highly active antiretroviral treatment (HAART).
  • Finally, in early AIDS-related dementia complex (ADC), striatal hypermetabolism is observed, whereas progressive ADC is characterized by a decrease in subcortical and cortical metabolism.
  • In the clinical setting, PET has been shown to allow the differentiation of AIDS-related opportunistic infections and malignancies, and to allow monitoring of side effects of HAART.
  • However, in patients suffering from HIV infection and presenting with extracerebral lymphoma or other human malignancies, knowledge of viraemia is essential when interpreting FDG PET imaging.
  • [MeSH-major] HIV Infections / diagnostic imaging. HIV-1. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 2008 Sep;33(9):610-4 [18716509.001]
  • [Cites] Int J STD AIDS. 1996 Aug-Sep;7(5):337-46 [8894823.001]
  • [Cites] Lancet. 2003 Sep 20;362(9388):959-61 [14511930.001]
  • [Cites] J Clin Invest. 2002 Nov;110(9):1319-27 [12417571.001]
  • [Cites] Curr HIV Res. 2004 Jan;2(1):61-78 [15053341.001]
  • [Cites] J Neuroimmunol. 2004 Dec;157(1-2):153-62 [15579293.001]
  • [Cites] J Nucl Med. 1993 Apr;34(4):567-75 [8455072.001]
  • [Cites] Brain. 2001 Oct;124(Pt 10):2014-27 [11571219.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1993 Summer;5(3):316-21 [8369642.001]
  • [Cites] Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-189-94 [18646347.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6425-30 [8692831.001]
  • [Cites] BMC Med. 2008 Oct 31;6:31 [18976462.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):180-7 [7626961.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):640-7 [19082590.001]
  • [Cites] Curr Opin Oncol. 2008 Sep;20(5):534-40 [19106656.001]
  • [Cites] Biomark Med. 2008;2(4):349-361 [19057654.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Semin Immunol. 2008 Jun;20(3):187-95 [18620868.001]
  • [Cites] Adv Cancer Res. 2008;101:349-95 [19055948.001]
  • [Cites] HIV Med. 2004 Mar;5(2):67-73 [15012644.001]
  • [Cites] Neurology. 1999 Dec 10;53(9):2199-203 [10599809.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):171-84 [18097219.001]
  • [Cites] Lancet. 2001 Aug 11;358(9280):461-7 [11513911.001]
  • [Cites] Arch Pharm Res. 2002 Jun;25(3):215-28 [12135090.001]
  • [Cites] J Neurovirol. 2005 Aug;11(4):346-55 [16162478.001]
  • [Cites] Neuroimage. 2008 Aug 15;42(2):869-78 [18579413.001]
  • [Cites] Ann Neurol. 1987 Dec;22(6):700-6 [3501695.001]
  • [Cites] J S C Med Assoc. 2008 Oct;104(7):223-6 [19058735.001]
  • [Cites] Int Rev Psychiatry. 2008 Feb;20(1):25-31 [18240060.001]
  • [Cites] AIDS. 2004 Dec 3;18(18):2430-2 [15622321.001]
  • [Cites] J Neurovirol. 2006 Aug;12 (4):262-71 [16966217.001]
  • [Cites] Lancet. 2003 Sep 20;362(9388):945-50 [14511927.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):701-6 [11299829.001]
  • [Cites] J Infect Dis. 2008 May 15;197 Suppl 3:S294-306 [18447615.001]
  • [Cites] AIDS. 2006 Feb 28;20(4):495-503 [16470113.001]
  • [Cites] Magn Reson Med. 1993 Mar;29(3):317-26 [8450740.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2093-9 [10382692.001]
  • [Cites] J Nucl Med. 1995 Dec;36(12 ):2169-74 [8523099.001]
  • [Cites] Indian J Pathol Microbiol. 2005 Apr;48(2):151-60 [16758653.001]
  • [Cites] J Nucl Med. 1996 Jul;37(7):1133-41 [8965184.001]
  • [Cites] Drug Saf. 2000 Jul;23(1):57-76 [10915032.001]
  • [Cites] J Neuroimmune Pharmacol. 2006 Jun;1(2):117-26 [18040778.001]
  • [Cites] AIDS Patient Care STDS. 2008 Sep;22(9):695-700 [18793085.001]
  • [Cites] J Nucl Med. 1991 Sep;32(9):1725-9 [1880574.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Semin Nucl Med. 1990 Oct;20(4):353-63 [2237453.001]
  • [Cites] Curr HIV/AIDS Rep. 2006 Feb;3(1):5-12 [16522253.001]
  • [Cites] Brain. 2004 Nov;127(Pt 11):2452-8 [15319273.001]
  • [Cites] Virology. 2000 Sep 1;274(2):255-61 [10964769.001]
  • [Cites] Arch Neurol. 2000 Nov;57(11):1601-7 [11074792.001]
  • [Cites] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):532-6 [7622678.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1854-61 [7562055.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 Aug;5(3):140-9 [18627663.001]
  • [Cites] J Nucl Med. 1989 May;30(5):581-90 [2785582.001]
  • [Cites] Mol Med Today. 2000 Mar;6(3):108-11 [10689313.001]
  • [Cites] J Nucl Med. 1997 Oct;38(10 ):1575-83 [9379195.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1992 Summer;4(3):280-7 [1498579.001]
  • [Cites] Exp Cell Res. 1991 Apr;193(2):425-31 [2004656.001]
  • [Cites] J Nucl Med. 1996 Jul;37(7):1177-80 [8965193.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Semin Nucl Med. 1998 Oct;28(4):352-8 [9800240.001]
  • (PMID = 19350235.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 63
  •  go-up   go-down


29. Singh J, Malani AK, Ganguly S, Kambhampati S: HAART- and AIDS-related lymphomas. Blood; 2006 Nov 15;108(10):3621; author reply 3621-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HAART- and AIDS-related lymphomas.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • (PMID = 17085718.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


30. Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, De Paoli A, Dal Maso L, Franceschi S, Rezza G: Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study. J Acquir Immune Defic Syndr; 2009 Sep 1;52(1):99-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study.
  • OBJECTIVES: To provide survival estimates of Italian people with AIDS (PWA) in the highly active antiretroviral therapy era and to identify prognostic factors at diagnosis and illnesses present at death.
  • Non-Hodgkin lymphoma at AIDS diagnosis was the strongest negative prognostic factor, particularly in the first 12 months after AIDS (hazard ratio = 9.2, for primary brain lymphoma).
  • At death, non-AIDS-defining illnesses increased from 38.4% in 1999 to 56.9% in 2006, with non-AIDS-defining cancers rising from 3.7% to 8.7%.
  • CONCLUSIONS: Our study documented the prolonged survival of Italian PWA, the strong impact of non-Hodgkin lymphoma on mortality, and the increasing frequency of non-AIDS-defining illnesses at death.
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / mortality. Female. Humans. Italy / epidemiology. Longitudinal Studies. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / mortality. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448558.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Salemi M, Lamers SL, Huysentruyt LC, Galligan D, Gray RR, Morris A, McGrath MS: Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma. PLoS One; 2009 Dec 03;4(12):e8153
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma.
  • Despite highly active antiretroviral therapy (HAART), AIDS related lymphoma (ARL) occurs at a significantly higher rate in patients infected with the Human Immunodeficiency Virus (HIV) than in the general population.
  • HIV-infected macrophages are a known viral reservoir and have been shown to have lymphomagenic potential in SCID mice; therefore, there is an interest in determining if a viral component to lymphomagenesis also exists.
  • We sequenced HIV-1 envelope gp120 clones obtained post mortem from several tumor and non-tumor tissues of two patients who died with AIDS-related Non-Hodgkin's lymphoma (ARL-NH).
  • 1) high-resolution phylogenetic analysis showed a significant degree of compartmentalization between lymphoma and non-lymphoma viral sub-populations while viral sub-populations from lymph nodes appeared to be intermixed within sequences from tumor and non-tumor tissues, 2) a 100-fold increase in the effective HIV population size in tumor versus non-tumor tissues was associated with the emergence of lymphadenopathy and aggressive metastatic ARL, and 3) HIV gene flow among lymph nodes, normal and metastatic tissues was non-random.
  • The different population dynamics between the viruses found in tumors versus the non-tumor associated viruses suggest that there is a significant relationship between HIV evolution and lymphoma pathogenesis.
  • Moreover, the study indicates that HIV could be used as an effective marker to study the origin and dissemination of lymphomas in vivo.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Genetics. 2006 Apr;172(4):2665-81 [16489234.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1369-75 [17128264.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):272-9 [17324334.001]
  • [Cites] PLoS Comput Biol. 2007 Feb 16;3(2):e29 [17305421.001]
  • [Cites] PLoS One. 2007;2(9):e950 [17895991.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]
  • [Cites] Retrovirology. 2007;4:87 [18053211.001]
  • [Cites] BMC Evol Biol. 2007;7:214 [17996036.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):285-93 [19308068.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] Genetics. 2000 Jul;155(3):1429-37 [10880500.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]
  • [Cites] Mol Biol Evol. 2001 Jun;18(6):1001-13 [11371589.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2310-4 [11743192.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]
  • [Cites] Science. 2004 Jan 16;303(5656):327-32 [14726583.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]
  • [Cites] Genetics. 1989 Nov;123(3):603-13 [2599370.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Mol Biol Evol. 2005 May;22(5):1185-92 [15703244.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • (PMID = 19997510.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA096230-06; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA009126; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA09126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120
  • [Other-IDs] NLM/ PMC2780293
  •  go-up   go-down


32. Kang KM, Song DS, Park JM, Jung CK, Hong YS, Kang MW, Park CW: Four cases of non-Hodgkin's lymphoma in AIDS patients. Korean J Intern Med; 2006 Dec;21(4):266-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four cases of non-Hodgkin's lymphoma in AIDS patients.
  • The incidence of opportunistic infection has decreased since the introduction of highly active antiretroviral therapy, so lymphoma is now far and away the most lethal complication of acquired immunodeficiency syndrome.
  • We have experienced four cases of NHL in AIDS patients.
  • The first patient was a 37 year old male who presented with left sided hemiplegia due to CNS lymphoma.
  • The second patient was a 40 year old male who was admitted because of jaundice; he was diagnosed as having lymphoma that exclusively involved the liver.
  • The third patient was a 38-year-old male who presented with palpable mass in the left cervical region, which was diagnosed as lymphoma.
  • Above three cases were confirmed as diffuse large B cell lymphoma.
  • The latter case is the first report of NHL involving the chest wall musculature in a Korean AIDS patient.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, Non-Hodgkin / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):863-73 [11298581.001]
  • [Cites] Korean J Intern Med. 2001 Mar;16(1):1-7 [11417298.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):349-51 [12688356.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1981 Jun 5;30(21):250-2 [6265753.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] JAMA. 1989 Feb 3;261(5):719-24 [2536124.001]
  • [Cites] Ann Intern Med. 1990 Aug 15;113(4):276-82 [1973886.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):515-24 [9711914.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • (PMID = 17249512.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891035
  •  go-up   go-down


33. Hamdy RC: Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther; 2010;4:321-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It virtually eliminates the problem of poor compliance with orally administered bisphosphonates and, because it bypasses the gastrointestinal tract, it is not associated with gastrointestinal side effects.

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs Aging. 2008;25(11):963-86 [18947264.001]
  • [Cites] Clin Interv Aging. 2008;3(3):445-51 [18982915.001]
  • [Cites] Kidney Int. 2008 Dec;74(11):1385-93 [18685574.001]
  • [Cites] J Clin Densitom. 2008 Oct-Dec;11(4):478-84 [18757222.001]
  • [Cites] J Rheumatol. 2008 Dec;35(12):2458-9 [19040323.001]
  • [Cites] J Am Dent Assoc. 2008 Dec;139(12):1674-7 [19047674.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):51-7 [19050386.001]
  • [Cites] Am J Med. 2009 Feb;122(2 Suppl):S14-21 [19187808.001]
  • [Cites] Am J Med. 2009 Feb;122(2 Suppl):S22-32 [19187809.001]
  • [Cites] Am J Med. 2009 Feb;122(2 Suppl):S3-13 [19187810.001]
  • [Cites] Ann Hematol. 2006 Sep;85(9):605-9 [16830143.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1193-202 [16956818.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Sep;7(2):145-7 [17026827.001]
  • [Cites] J Bone Joint Surg Br. 2007 Mar;89(3):349-53 [17356148.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1038-42 [17369566.001]
  • [Cites] Stroke. 2007 May;38(5):1519-25 [17395868.001]
  • [Cites] N Engl J Med. 2007 May 3;356(18):1809-22 [17476007.001]
  • [Cites] N Engl J Med. 2007 May 3;356(18):1878-80 [17476015.001]
  • [Cites] BJU Int. 2007 Jul;100(1):70-5 [17552955.001]
  • [Cites] Clin Genitourin Cancer. 2007 Mar;5(4):271-7 [17553207.001]
  • [Cites] Bone. 2007 Jul;41(1):122-8 [17468062.001]
  • [Cites] Osteoporos Int. 2007 Nov;18(11):1439-50 [17690930.001]
  • [Cites] J Bone Miner Res. 2007 Oct;22(10):1479-91 [17663640.001]
  • [Cites] J Dent Res. 2007 Nov;86(11):1022-33 [17959891.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1799-809 [17878149.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Dec;65(12):2397-410 [18022461.001]
  • [Cites] J Oncol Pharm Pract. 2007 Dec;13(4):223-9 [18045781.001]
  • [Cites] Am J Med. 2009 Feb;122(2 Suppl):S33-45 [19187811.001]
  • [Cites] Medscape J Med. 2009;11(1):12 [19295933.001]
  • [Cites] Lancet. 2009 Apr 11;373(9671):1253-63 [19362675.001]
  • [Cites] Clin Breast Cancer. 2009 May;9(2):77-85 [19433387.001]
  • [Cites] Clin Interv Aging. 2009;4:153-64 [19503777.001]
  • [Cites] J Bone Miner Res. 2009 Jul;24(7):1308-13 [19257818.001]
  • [Cites] Med Lett Drugs Ther. 2009 Jun 29;51(1315):49 [19556940.001]
  • [Cites] Mayo Clin Proc. 2009 Jul;84(7):632-7; quiz 638 [19567717.001]
  • [Cites] Hormones (Athens). 2009 Apr-Jun;8(2):96-110 [19570737.001]
  • [Cites] J Bone Miner Res. 2009 Sep;24(9):1544-51 [19338427.001]
  • [Cites] Clin Interv Aging. 2009;4:289-303 [19750231.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Sep;9(9):1211-8 [19761424.001]
  • [Cites] J Urol. 2009 Nov;182(5):2257-64 [19758618.001]
  • [Cites] Oncologist. 2009 Nov;14(11):1154-66 [19897878.001]
  • [Cites] Joint Bone Spine. 2010 Jan;77(1):53-7 [20034831.001]
  • [Cites] Obstet Gynecol. 2009 Nov;114(5):999-1007 [20168099.001]
  • [Cites] J Bone Miner Res. 2010 Jan;25(1):2-10 [20091928.001]
  • [Cites] J Am Geriatr Soc. 2010 Feb;58(2):292-9 [20070415.001]
  • [Cites] Ann Hematol. 2007 Jan;86(1):23-30 [17013645.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1854-5 [16936183.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Mar;65(3):369-76 [17307580.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Mar;65(3):415-23 [17307586.001]
  • [Cites] J Bone Miner Res. 2007 Mar;22(3):465-75 [17144789.001]
  • [Cites] Breast. 2010 Apr;19(2):92-6 [20079640.001]
  • [Cites] Osteoporos Int. 2010 Jun;21(6):1057-8 [19859646.001]
  • [Cites] Osteoporos Int. 2010 Sep;21(9):1617-9 [19936866.001]
  • [Cites] JAMA. 2001 Feb 14;285(6):785-95 [11176917.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1761-7 [12049882.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2392-3; author reply 2393-4 [14634434.001]
  • [Cites] J Am Acad Dermatol. 2004 Apr;50(4):651-2 [15034526.001]
  • [Cites] J Rheumatol. 2004 Apr;31(4):829-30 [15095748.001]
  • [Cites] BMJ. 2004 Jul 17;329(7458):156-7 [15258072.001]
  • [Cites] Am J Med. 1991 Jan;90(1):107-10 [1986575.001]
  • [Cites] Am J Phys Med Rehabil. 1993 Aug;72(4):188-91 [8363812.001]
  • [Cites] Am J Phys Med Rehabil. 1995 Sep-Oct;74(5):351-6 [7576411.001]
  • [Cites] Bone. 1995 Nov;17(5 Suppl):505S-511S [8573428.001]
  • [Cites] N Engl J Med. 1996 Oct 3;335(14):1016-21 [8793925.001]
  • [Cites] Clin Rheumatol. 1999;18(4):349-50 [10468180.001]
  • [Cites] Arch Intern Med. 2005 Feb 14;165(3):346-7 [15710802.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1294-301 [15598694.001]
  • [Cites] South Med J. 2005 Jul;98(7):733-5 [16108245.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75 [16243172.001]
  • [Cites] BMC Cancer. 2005;5:156 [16332258.001]
  • [Cites] Ann Intern Med. 2006 Feb 21;144(4):239-48 [16490909.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):753-61 [16702591.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-34 [16684881.001]
  • [Cites] J Am Dent Assoc. 2006 Aug;137(8):1144-50 [16873332.001]
  • [Cites] J Bone Miner Res. 2008 Jan;23(1):6-16 [17892374.001]
  • [Cites] J Am Dent Assoc. 2008 Jan;139(1):32-40 [18167382.001]
  • [Cites] Ann Intern Med. 2008 Feb 5;148(3):197-213 [18087050.001]
  • [Cites] Injury. 2008 Feb;39(2):224-31 [18222447.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1001-10 [18205185.001]
  • [Cites] J Rheumatol. 2008 Mar;35(3):537-8 [18203307.001]
  • [Cites] Expert Opin Pharmacother. 2008 Apr;9(6):1013-28 [18377343.001]
  • [Cites] Arch Intern Med. 2008 Apr 28;168(8):826-31 [18443257.001]
  • [Cites] J Orthop Trauma. 2008 May-Jun;22(5):346-50 [18448990.001]
  • [Cites] Med Oncol. 2008;25(2):238-40 [18488162.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Aug;93(8):2948-52 [18522980.001]
  • [Cites] Kidney Int. 2008 Sep;74(5):641-8 [18509324.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Sep;106(3):389-91 [18554944.001]
  • [Cites] Lancet Oncol. 2008 Sep;9(9):840-9 [18718815.001]
  • [Cites] Arch Intern Med. 2000 Feb 28;160(4):517-25 [10695692.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6289-95 [18829511.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4739-45 [18711172.001]
  • (PMID = 21151620.001).
  • [ISSN] 1177-8881
  • [Journal-full-title] Drug design, development and therapy
  • [ISO-abbreviation] Drug Des Devel Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  • [Other-IDs] NLM/ PMC2998805
  • [Keywords] NOTNLM ; bisphosphonates / osteopenia / osteoporosis / zoledronate / zoledronic acid
  •  go-up   go-down


34. Trobridge GD, Wu RA, Beard BC, Chiu SY, Muñoz NM, von Laer D, Rossi JJ, Kiem HP: Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One; 2009 Nov 02;4(11):e7693
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection.
  • BACKGROUND: There is currently no effective AIDS vaccine, emphasizing the importance of developing alternative therapies.
  • Recently, a patient was successfully transplanted with allogeneic, naturally resistant CCR5-negative (CCR5Delta32) cells, setting the stage for transplantation of naturally resistant, or genetically modified stem cells as a viable therapy for AIDS.
  • Hematopoietic stem cell (HSC) gene therapy using vectors that express various anti-HIV transgenes has also been attempted in clinical trials, but inefficient gene transfer in these studies has severely limited the potential of this approach.
  • Here we evaluated HSC gene transfer of an anti-HIV vector in the pigtailed macaque (Macaca nemestrina) model, which closely models human transplantation.
  • METHODS AND FINDINGS: We used lentiviral vectors that inhibited both HIV-1 and simian immunodeficiency virus (SIV)/HIV-1 (SHIV) chimera virus infection, and also expressed a P140K mutant methylguanine methyltransferase (MGMT) transgene to select gene-modified cells by adding chemotherapy drugs.
  • The high marking levels allowed us to demonstrate protection from SHIV in lymphocytes derived from gene-modified macaque long-term repopulating cells that expressed an HIV-1 fusion inhibitor.
  • We observed a statistically significant 4-fold increase of gene-modified cells after challenge of lymphocytes from one macaque that received stem cells transduced with an anti-HIV vector (p<0.02, Student's t-test), but not in lymphocytes from a macaque that received a control vector.
  • We also established a competitive repopulation assay in a second macaque for preclinical testing of promising anti-HIV vectors.
  • The vectors we used were HIV-based and thus efficiently transduce human cells, and the transgenes we used target HIV-1 genes that are also in SHIV, so our findings can be rapidly translated to the clinic.
  • CONCLUSIONS: Here we demonstrate the ability to select protected HSC-derived lymphocytes in vivo in a clinically relevant nonhuman primate model of HIV/SHIV infection.
  • This approach can now be evaluated in human clinical trials in AIDS lymphoma patients.
  • In this patient setting, chemotherapy would not only kill malignant cells, but would also increase the number of MGMTP140K-expressing HIV-resistant cells.
  • This approach should allow for high levels of HIV-protected cells in AIDS patients to evaluate AIDS gene therapy.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Jul 10;288(2):222-35 [12095387.001]
  • [Cites] Gene Ther. 2010 Jan;17(1):37-49 [19741733.001]
  • [Cites] J Med Primatol. 2002 Aug;31(4-5):237-56 [12390546.001]
  • [Cites] Science. 2003 Jun 13;300(5626):1749-51 [12805549.001]
  • [Cites] Science. 2003 Jun 27;300(5628):2036-9 [12829768.001]
  • [Cites] Nat Rev Drug Discov. 2003 Aug;2(8):624-34 [12904812.001]
  • [Cites] Mol Ther. 2003 Aug;8(2):196-206 [12907142.001]
  • [Cites] J Clin Invest. 2003 Nov;112(10):1581-8 [14617759.001]
  • [Cites] J Virol. 2004 Jan;78(2):568-75 [14694088.001]
  • [Cites] Hum Gene Ther. 2004 Mar;15(3):251-62 [15018734.001]
  • [Cites] Curr Gene Ther. 2004 Mar;4(1):15-31 [15032611.001]
  • [Cites] Blood. 2004 May 15;103(10):3710-6 [14739227.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4062-9 [14976042.001]
  • [Cites] J Immunol. 1985 Feb;134(2):971-6 [3871222.001]
  • [Cites] Immunogenetics. 1985;21(3):235-46 [3872841.001]
  • [Cites] Hum Gene Ther. 1999 Nov 20;10(17):2769-78 [10584923.001]
  • [Cites] Microbes Infect. 2000 Feb;2(2):223-9 [10742694.001]
  • [Cites] AIDS. 1999;13 Suppl A:S113-20 [10885770.001]
  • [Cites] Hum Gene Ther. 2000 Sep 20;11(14):2025-37 [11020801.001]
  • [Cites] Ann N Y Acad Sci. 2000 Nov;918:318-29 [11131719.001]
  • [Cites] J Pharmacol Exp Ther. 2001 May;297(2):524-30 [11303039.001]
  • [Cites] Hum Gene Ther. 2001 Jun 10;12(9):1013-9 [11399224.001]
  • [Cites] Mol Ther. 2002 Jan;5(1):33-41 [11786043.001]
  • [Cites] J Virol. 1992 Apr;66(4):2232-9 [1548759.001]
  • [Cites] J Virol. 1992 Dec;66(12):7517-21 [1433527.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6221-7 [7954470.001]
  • [Cites] J Med Primatol. 1996 Jun;25(3):163-74 [8892037.001]
  • [Cites] J Virol. 1997 May;71(5):3932-9 [9094670.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1936-45 [9581836.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Curr Opin Biotechnol. 1998 Oct;9(5):457-63 [9821272.001]
  • [Cites] Science. 1999 Jan 29;283(5402):682-6 [9924027.001]
  • [Cites] Blood. 2005 Feb 1;105(3):997-1002 [15494421.001]
  • [Cites] Methods Mol Biol. 2005;309:261-72 [15990406.001]
  • [Cites] Hum Gene Ther. 2005 Dec;16(12):1355-66 [16390267.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Nat Biotechnol. 2006 Jun;24(6):687-96 [16732270.001]
  • [Cites] Hum Gene Ther. 2006 Jun;17(6):577-88 [16776567.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Retrovirology. 2006;3:76 [17078891.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):76-85 [17164778.001]
  • [Cites] Blood. 2007 Jan 1;109(1):65-70 [16968897.001]
  • [Cites] J Virol. 2007 Mar;81(6):2700-12 [17182671.001]
  • [Cites] PLoS Pathog. 2007 Apr;3(4):e54 [17432934.001]
  • [Cites] Hum Gene Ther. 2007 May;18(5):451-6 [17536975.001]
  • [Cites] Exp Hematol. 2007 Jul;35(7):1132-9 [17588482.001]
  • [Cites] J Virol. 2007 Nov;81(22):12210-7 [17804491.001]
  • [Cites] Nat Med. 2007 Dec;13(12):1389-90 [18064013.001]
  • [Cites] Nat Biotechnol. 2007 Dec;25(12):1444-54 [18066041.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5537-43 [18388180.001]
  • [Cites] Gene Ther. 2008 Dec;15(23):1536-49 [18800151.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] Nat Med. 2009 Mar;15(3):285-92 [19219022.001]
  • [Cites] Hum Gene Ther. 2009 Apr;20(4):325-36 [19267665.001]
  • [Cites] Cell. 2002 Aug 23;110(4):521-9 [12202041.001]
  • (PMID = 19888329.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK047754; United States / NIAID NIH HHS / AI / R21 AI063959; United States / NIAID NIH HHS / AI / AI063959; United States / NIAID NIH HHS / AI / AI061839; United States / NHLBI NIH HHS / HL / P01 HL053750; United States / NIDDK NIH HHS / DK / DK056465; United States / NIDDK NIH HHS / DK / DK047754; United States / NIDDK NIH HHS / DK / P30 DK056465; United States / NIAID NIH HHS / AI / R01 AI080326; United States / NIAID NIH HHS / AI / P01 AI061839; United States / NHLBI NIH HHS / HL / HL053750
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines
  • [Other-IDs] NLM/ PMC2765621
  •  go-up   go-down


35. Rothschild S, Dolder M, Seifert B, Lütolf UM, Ciernik IF: Radiation therapy for HIV-associated diffuse large cell non-Hodgkin lymphoma. J Int Assoc Physicians AIDS Care (Chic); 2009 Jul-Aug;8(4):239-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for HIV-associated diffuse large cell non-Hodgkin lymphoma.
  • PURPOSE: To report the clinical experience with external beam radiotherapy (RT) for AIDS-related lymphoma (ARL) with or without the involvement of the central nervous system (CNS) in HIV-infected patients.
  • PATIENTS AND METHODS: Clinical outcome of 24 HIV-seropositive patients with ARL treated with RT from 1995 to 2004 was reviewed, testing factors associated with outcome.
  • Radiotherapy dose was associated with survival in univariate (P = .04) and multivariate analysis (P = .01).
  • Other factors in univariate analysis associated with outcome were viral load (VL), highly active antiretroviral therapy (HAART), ARL stage, and CNS involvement.
  • [MeSH-major] Lymphoma, AIDS-Related / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adult. Aged. CD4 Lymphocyte Count. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Female. HIV Seropositivity. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Viral Load


36. Madan RA, Chang VT, Dever LL: An uncommon presentation of HIV-related lymphoma. AIDS Patient Care STDS; 2007 Jul;21(7):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon presentation of HIV-related lymphoma.
  • Although highly active antiretroviral therapy has improved the clinical course of patients with HIV, this population remains at a significantly increased risk for non-Hodgkin's lymphoma (NHL).
  • We encountered a patient with HIV-related NHL who presented with a thoracic spinal cord compression and had a complicated clinical course as a result of the atypical presentation.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / complications. Lymphoma, Non-Hodgkin / virology. Spinal Cord Compression / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651024.001).
  • [ISSN] 1087-2914
  • [Journal-full-title] AIDS patient care and STDs
  • [ISO-abbreviation] AIDS Patient Care STDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Levine AM: Management of AIDS-related lymphoma. Curr Opin Oncol; 2008 Sep;20(5):522-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related lymphoma.
  • PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.
  • Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.
  • RECENT FINDINGS: Use of highly active antiretroviral therapy, either concomitantly or immediately after completion of chemotherapy, has resulted in rates of complete remission and survival that are similar to those in HIV-negative patients.
  • The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed.
  • The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results.
  • High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.
  • Addition of rituximab is associated with improved response rates, without an increase in infections.
  • Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.
  • Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106654.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


38. Mani D, Dorer RK, Aboulafia DM: Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma; 2009 Aug;9(4):316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukemia following HIV-associated lymphoma.
  • In the highly active antiretroviral therapy era, an increasingly large number of HIV-infected patients are developing non- AIDS-defining cancers (NADCs).
  • As patients survive longer, long-term therapy-related complications take on greater importance.
  • Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
  • With the diagnosis of therapy-related acute myeloid leukemia (AML) secured, he began induction chemotherapy with idarubicin and cytarabine.
  • Through a literature search, we were able to identify 4 additional cases of therapy-related AML in AIDS patients following chemotherapy for lymphomas.
  • The median age of these patients at the time of AML diagnosis was 39 years (range, 33-59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11-48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2-16 weeks).
  • With many HIV-infected patients surviving alkylator and topoisomerase inhibitor-based treatment and radiation therapy for AIDS-defining cancers and NADCs, long-term follow-up for therapy-related complications assumes greater importance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717383.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


39. Goldstein MA, Naidich TP, Silverman ME: Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS.
  • Accurately distinguishing between cerebral toxoplasmosis and primary central nervous system lymphoma (PCNSL), still the most common secondary CNS mass lesion complications of AIDS, has long represented a diagnostic challenge in those with HIV.
  • A young adult male with AIDS presented with evolving ophthalmoplegias, Parinaud's syndrome and gait dysfunction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2003 Apr;24(4):554-5 [12695179.001]
  • [Cites] Neurology. 1998 Jan;50(1):21-6 [9443452.001]
  • (PMID = 21686485.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027744
  •  go-up   go-down


40. Dikshit B, Wanchu A, Sachdeva RK, Sharma A, Das R: Profile of hematological abnormalities of Indian HIV infected individuals. BMC Blood Disord; 2009;9:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profile of hematological abnormalities of Indian HIV infected individuals.
  • BACKGROUND: Hematological abnormalities are a common complication of HIV infection.
  • These abnormalities increase as the disease advances.
  • Bone marrow abnormalities occur in all stages of HIV infection.
  • METHODS: Two hundred HIV infected individual were screened for hematological abnormalities from March 2007-March 2008.
  • Iron deficiency anemia was seen in 49.2% (/200) cases while anemia of chronic disease occurred in 50.7% (/200) cases.
  • Bone marrow evaluation was carried out in 14 patients out of which staging marrow was performed in 2 cases of non-Hodgkin's lymphoma (NHL) and did not show any bone marrow infiltration.
  • CONCLUSION: Anemia in HIV patients can be a good clinical indicator to predict and access the underlying immune status.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2008 May;118(5):1622-5 [18431512.001]
  • [Cites] J Assoc Physicians India. 2005 Feb;53:105-10 [15847027.001]
  • [Cites] AIDS. 1999 May 28;13(8):943-50 [10371175.001]
  • [Cites] Blood. 1998 Jan 1;91(1):301-8 [9414298.001]
  • [Cites] Addiction. 2000 Mar;95(3):383-92 [10795359.001]
  • [Cites] Blood. 1993 May 15;81(10):2664-70 [8490176.001]
  • [Cites] J Infect Dis. 1988 Sep;158(3):627-30 [2842409.001]
  • [Cites] West J Med. 1987 Aug;147(2):157-60 [3660772.001]
  • [Cites] Clin Infect Dis. 2002 Jan 15;34(2):260-6 [11740716.001]
  • [Cites] Acta Haematol Pol. 1993;24(2 Suppl 1):33-9 [8362615.001]
  • (PMID = 19678930.001).
  • [ISSN] 1471-2326
  • [Journal-full-title] BMC blood disorders
  • [ISO-abbreviation] BMC Blood Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2741436
  •  go-up   go-down


41. Dunleavy K, Wilson WH, Kaplan LD: The case for rituximab in AIDS-related lymphoma. Blood; 2006 Apr 1;107(7):3014-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The case for rituximab in AIDS-related lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Humans. Lymphoma, Non-Hodgkin / drug therapy. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • (PMID = 16554492.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


42. Pierard V, Guiguen A, Colin L, Wijmeersch G, Vanhulle C, Van Driessche B, Dekoninck A, Blazkova J, Cardona C, Merimi M, Vierendeel V, Calomme C, Nguyên TL, Nuttinck M, Twizere JC, Kettmann R, Portetelle D, Burny A, Hirsch I, Rohr O, Van Lint C: DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcription factor binding. J Biol Chem; 2010 Jun 18;285(25):19434-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcription factor binding.
  • Importantly, cytosine hypermethylation in the 5'-long terminal repeat (LTR) U3 and R regions was associated with true latency in the lymphoma-derived B-cell line L267 but not with defective latency in YR2 cells.
  • [MeSH-major] Activating Transcription Factor 1 / metabolism. B-Lymphocytes / metabolism. B-Lymphocytes / virology. Cyclic AMP Response Element Modulator / metabolism. Cyclic AMP Response Element-Binding Protein / metabolism. Cytosine / metabolism. DNA / genetics. DNA Methylation. Leukemia Virus, Bovine / genetics. Lymphoma / metabolism. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1994 Sep;68(9):5845-53 [8057465.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 25;22(23):4872-5 [7800474.001]
  • [Cites] J Mol Biol. 1996 Mar 1;256(3):503-16 [8604134.001]
  • [Cites] J Virol. 1996 Apr;70(4):2170-7 [8642639.001]
  • [Cites] PLoS Pathog. 2009 Mar;5(3):e1000356 [19325883.001]
  • [Cites] PLoS Pathog. 2009 Jun;5(6):e1000495 [19557157.001]
  • [Cites] PLoS Pathog. 2009 Aug;5(8):e1000554 [19696893.001]
  • [Cites] Retrovirology. 2009;6:71 [19650892.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2882-96 [12771939.001]
  • [Cites] Science. 2003 Oct 31;302(5646):890-3 [14593184.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):559-67 [14991578.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):35025-36 [15163662.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Blood. 1979 May;53(5):899-912 [219923.001]
  • [Cites] J Am Vet Med Assoc. 1979 Dec 15;175(12):1281-6 [231025.001]
  • [Cites] Cancer Res. 1980 Jul;40(7):2240-4 [6248201.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 May;77(5):2577-81 [6248854.001]
  • [Cites] Science. 1982 Jan 22;215(4531):405-7 [6276975.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Apr;79(8):2465-9 [6283527.001]
  • [Cites] J Virol. 1985 Jun;54(3):899-901 [2987544.001]
  • [Cites] Biochem Biophys Res Commun. 1985 May 31;129(1):126-33 [2988545.001]
  • [Cites] J Virol. 1987 Aug;61(8):2462-71 [3037109.001]
  • [Cites] Cancer Surv. 1987;6(1):139-59 [2891439.001]
  • [Cites] Haematol Blood Transfus. 1987;31:482-7 [2832278.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9263-7 [2848258.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(7):2336-40 [2494664.001]
  • [Cites] J Virol. 1989 May;63(5):2099-107 [2539506.001]
  • [Cites] J Virol. 1996 Mar;70(3):1990-9 [8627725.001]
  • [Cites] Nucleic Acids Res. 1996 Dec 15;24(24):5064-6 [9016686.001]
  • [Cites] Virology. 1997 Dec 22;239(2):249-58 [9434716.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8211-8 [10567546.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):88-91 [10615135.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):697-704 [10617669.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1787-95 [11080828.001]
  • [Cites] Cell. 2001 Aug 10;106(3):309-18 [11509180.001]
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):8775-89 [11741930.001]
  • [Cites] J Virol. 2002 May;76(10):5034-42 [11967319.001]
  • [Cites] J Virol. 2002 Sep;76(18):9389-97 [12186921.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7241-6 [12370815.001]
  • [Cites] J Virol. 2003 Apr;77(7):4423-30 [12634400.001]
  • [Cites] J Virol. 1998 Jul;72(7):5526-34 [9621009.001]
  • [Cites] J Virol. 1998 Jul;72(7):5994-6003 [9621062.001]
  • [Cites] J Virol. 1999 Feb;73(2):1054-65 [9882306.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2571-87 [15526163.001]
  • [Cites] J Virol. 2004 Dec;78(24):13848-64 [15564493.001]
  • [Cites] Oncogene. 2005 Mar 10;24(11):1914-23 [15674330.001]
  • [Cites] J Virol. 2005 Jun;79(12):7338-48 [15919888.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10309-14 [16006517.001]
  • [Cites] Retrovirology. 2005;2:64 [16242045.001]
  • [Cites] Retrovirology. 2006;3:5 [16409643.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;301:45-66 [16570845.001]
  • [Cites] EMBO J. 2006 Jun 7;25(11):2443-52 [16724115.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):581-5 [16865259.001]
  • [Cites] EMBO J. 2007 Jan 24;26(2):412-23 [17245431.001]
  • [Cites] Retrovirology. 2007;4:18 [17362524.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1476-94 [17408664.001]
  • [Cites] J Virol. 2007 Jun;81(11):5929-39 [17392371.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):20854-67 [17526487.001]
  • [Cites] Retrovirology. 2007;4:51 [17645797.001]
  • [Cites] Cell Tissue Res. 2008 Jan;331(1):31-55 [18060563.001]
  • [Cites] Retrovirology. 2008;5:76 [18702816.001]
  • [Cites] J Virol Methods. 1989 Feb;23(2):211-22 [2542354.001]
  • [Cites] Cancer Res. 1990 Aug 15;50(16):4968-73 [1696163.001]
  • [Cites] J Virol. 1992 Feb;66(2):766-72 [1309910.001]
  • [Cites] J Virol. 1992 Jul;66(7):4427-33 [1318412.001]
  • [Cites] Genes Dev. 1993 Feb;7(2):173-9 [8436289.001]
  • [Cites] J Virol. 1993 Jul;67(7):4078-85 [8389918.001]
  • [Cites] J Virol. 1994 Apr;68(4):2632-48 [8139041.001]
  • (PMID = 20413592.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATF1 protein, human; 0 / Activating Transcription Factor 1; 0 / Chromatin; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Sulfites; 135844-64-3 / Cyclic AMP Response Element Modulator; 8J337D1HZY / Cytosine; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP; OJ9787WBLU / hydrogen sulfite
  • [Other-IDs] NLM/ PMC2885223
  •  go-up   go-down


43. Silverman LR, Phipps AJ, Montgomery A, Fernandez S, Tsukahara T, Ratner L, Lairmore MD: In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations. Blood; 2005 Nov 15;106(10):3602-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell lymphoma/leukemia (ATL).
  • However, SU point mutations resulted in decreased antibody responses to viral group-associated antigen (Gag) and Env antigens.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):74-83 [12925959.001]
  • [Cites] Virology. 1984 Jul 30;136(2):338-47 [6087548.001]
  • [Cites] Mol Biol Med. 1988 Feb;5(1):29-42 [2897612.001]
  • [Cites] J Gen Virol. 1988 Jul;69 ( Pt 7):1695-710 [2899128.001]
  • [Cites] J Immunol. 1989 Feb 1;142(3):971-8 [2563272.001]
  • [Cites] J Virol. 1990 Mar;64(3):1278-82 [2304144.001]
  • [Cites] J Clin Microbiol. 1990 Apr;28(4):646-50 [2185257.001]
  • [Cites] EMBO J. 1990 Dec;9(13):4243-8 [2124968.001]
  • [Cites] Virology. 1991 May;182(1):413-9 [2024477.001]
  • [Cites] J Immunol. 1991 Jul 1;147(1):354-60 [1711082.001]
  • [Cites] Blood. 1991 Oct 15;78(8):2082-8 [1680498.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] N Engl J Med. 1992 Feb 6;326(6):375-80 [1729620.001]
  • [Cites] J Immunol. 1992 Aug 1;149(3):940-8 [1378869.001]
  • [Cites] J Immunol. 1993 Jul 15;151(2):1013-24 [7687611.001]
  • [Cites] J Virol. 1994 Jun;68(6):3544-9 [8189493.001]
  • [Cites] Baillieres Clin Haematol. 1993 Dec;6(4):899-915 [8038496.001]
  • [Cites] J Virol. 1994 Oct;68(10):6323-31 [8083972.001]
  • [Cites] Virology. 1994 Nov 1;204(2):656-64 [7941334.001]
  • [Cites] J Virol. 1996 Oct;70(10):7241-6 [8794375.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S85-91 [8797709.001]
  • [Cites] J Virol. 1997 Jan;71(1):259-66 [8985345.001]
  • [Cites] J Med Virol. 1997 Jan;51(1):25-31 [8986945.001]
  • [Cites] J Infect Dis. 1997 Mar;175(3):716-9 [9041352.001]
  • [Cites] Am J Trop Med Hyg. 1997 Aug;57(2):142-8 [9288805.001]
  • [Cites] J Virol. 1997 Oct;71(10):7180-6 [9311790.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4701-7 [9616168.001]
  • [Cites] J Neurol Sci. 1998 Jul 15;159(1):67-72 [9700706.001]
  • [Cites] J Neurovirol. 1998 Dec;4(6):586-93 [10065900.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3963-9 [12907436.001]
  • [Cites] Cell. 2003 Nov 14;115(4):449-59 [14622599.001]
  • [Cites] J Virol. 2004 Apr;78(8):3837-45 [15047799.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):336-61 [15129647.001]
  • [Cites] J Virol. 1999 Nov;73(11):9369-76 [10516045.001]
  • [Cites] Proc Assoc Am Physicians. 1996 Nov;108(6):444-8 [8956367.001]
  • [Cites] Transfusion. 1999 Nov-Dec;39(11-12):1185-93 [10604244.001]
  • [Cites] J Virol. 2000 Feb;74(3):1094-100 [10627519.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 1;16(7):665-75 [10791877.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 7;93(5):367-77 [11238698.001]
  • [Cites] Virus Res. 2001 Oct 30;78(1-2):5-16 [11520576.001]
  • [Cites] J Virol. 2001 Oct;75(19):9553-9 [11533220.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] Clin Lab Haematol. 2003 Apr;25(2):111-7 [12641615.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3856-60 [6328528.001]
  • (PMID = 16046523.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100730-02; United States / NCI NIH HHS / CA / CA-63417; United States / NCI NIH HHS / CA / CA09338; United States / NCI NIH HHS / CA / CA70529
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Gene Products, env; 0 / Gene Products, gag
  • [Other-IDs] NLM/ PMC1895059
  •  go-up   go-down


44. Bo P, Junhua Z, Qiruo G, Hong L: Can Urol Assoc J; 2009 Jun;3(3):E14-E16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] A case report of retroperitoneal Castleman disease.
  • Castleman disease (CD) is an uncommon lymphoproliferative disorder and is especially rare in the retroperitoneum or perirenal area.
  • Castleman disease is commonly misdiagnosed as malignant lymphoma, lymphadenitis or ectopic thymoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543453.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


45. Castillo J, Hansen C, Mega A, Tashima K: AIDS-related lymphomas: the Rhode Island experience. Med Health R I; 2008 Nov;91(11):332-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas: the Rhode Island experience.
  • [MeSH-major] Lymphoma, AIDS-Related

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19093379.001).
  • [ISSN] 1086-5462
  • [Journal-full-title] Medicine and health, Rhode Island
  • [ISO-abbreviation] Med Health R I
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ: Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci; 2007 Oct;334(4):317-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric Castleman's disease masquerading as HIV-related lymphoma.
  • Patients with human immunodeficiency virus (HIV) infection are at increased risk for developing lymphoproliferative disorders.
  • Multicentric Castleman's disease should always be kept in the differential diagnosis of HIV-positive patients suspected of having lymphoma to avoid misdiagnosis.
  • We report the case of a 40-year-old HIV-positive homosexual man who presented with lower back pain and features highly suggestive of lymphoma including lymphadenopathy, elevated lactic dehydrogenase, and splenomegaly.
  • The patient's plasma was positive by polymerase chain reaction for Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/ HHV8), and a lymph node biopsy revealed Multicentric Castleman's disease.
  • Albeit a rare condition, Castleman's disease should always be considered in immunocompromised patients suspected of having lymphoma.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Lymphoma, AIDS-Related / diagnosis


47. Rafaniello Raviele P, Pruneri G, Maiorano E: Plasmablastic lymphoma: a review. Oral Dis; 2009 Jan;15(1):38-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: a review.
  • Plasmablastic lymphoma (PBL) has been recently characterised as an aggressive subtype of non-Hodgkin's lymphoma, most frequently arising in the oral cavity of HIV-infected patients.
  • Similar to other types of AIDS-related lymphomas, there is evidence that Epstein-Barr virus and Kaposi-sarcoma associated Human Herpes Virus 8 may play a relevant role in the pathogenesis of PBL.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939960.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / SDC1 protein, human; 0 / Syndecan-1
  • [Number-of-references] 54
  •  go-up   go-down


48. Verma N, Chaudhary UB, Costa LJ, Gudena V, Lazarchick J: Primary testicular lymphoma and AIDS. Ann Clin Lab Sci; 2010;40(1):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma and AIDS.
  • Immunosuppressed patients have an increased risk for developing extranodal lymphoma, including testicular lymphoma.
  • In AIDS patients, primary testicular lymphoma has been reported as an initial manifestation of the disease.
  • These patients typically present at an early age; their lymphomas usually have aggressive histologic appearance and are associated with poor prognosis.
  • We report a testicular lymphoma consistent with diffuse large B-cell lymphoma (DLBCL) in an AIDS patient and we review the literature on primary testicular lymphoma in AIDS patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology


49. Carbone A, Gloghini A: AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol; 2005 Sep;130(5):662-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas: from pathogenesis to pathology.
  • Human immunodeficiency virus (HIV)-associated lymphomas include:.
  • (1) lymphomas also occurring, although sporadically, in the absence of HIV infection.
  • The vast majority of these lymphomas are high-grade B-cell lymphomas: Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) with centroblastic (CB) features and DLBCL with immunoblastic (IBL) features;.
  • (2) unusual lymphomas occurring more specifically in HIV-positive patients and include two rare entities, namely 'primary effusion lymphoma' (PEL) and 'plasmablastic lymphoma' of the oral cavity.
  • The pathological heterogeneity of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas (AIDS-NHL) reflects the heterogeneity of their associated molecular lesions.
  • In AIDS-BL, the molecular lesions involve activation of cMYC, inactivation of P53, and infection with Epstein-Barr virus (EBV).
  • AIDS-IBL infected with EBV are characterised by frequent expression of latent membrane protein 1--an EBV oncoprotein.
  • The biological heterogeneity of AIDS-NHL is highlighted by their histogenetic differences.
  • Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8)-associated lymphomas, which often develop in persons with advanced AIDS, present predominantly as PEL.
  • KSHV/HHV8 has also been recently detected in solid extracavitary-based lymphomas.
  • The KSHV/HHV8-associated solid lymphomas are (1) unusual lymphomas that occur more specifically in HIV-positive patients;.
  • (2) extracavitary and arise in nodal and/or extranodal sites; and (3) histologically, they usually display a PEL-like morphology and plasma cell-related phenotype.
  • [MeSH-major] HIV-1. Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin. Sarcoma, Kaposi


50. Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL: Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis; 2008 Apr;8(4):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection.
  • Plasmablastic lymphoma of the oral cavity is a form of non-Hodgkin lymphoma (NHL) and was first described in 1997.
  • We describe a case of plasmablastic lymphoma in an HIV-infected patient who presented with an expanding oral lesion and symptoms of a toothache.
  • We review all cases of plasmablastic lymphoma that have been reported in the literature.
  • Plasmablastic lymphoma is strongly associated with immunodeficiency, and most particularly, with HIV infection.
  • The pathophysiological origin of plasmablastic lymphoma has not been fully characterised, but the presence of Epstein-Barr virus (EBV) has often been documented in biopsy specimens, supporting a role for EBV in the pathogenesis of this lymphoma.
  • Infectious disease clinicians should be aware of this newly described and increasingly encountered lymphoma, since it is prominently associated with immunosuppression and may be mistaken for other entities.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Mouth / pathology. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Head / radiography. Humans. Male. Tomography, X-Ray Computed. Toothache / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Lancet Infect Dis. 2010 Apr;10(4):226
  • (PMID = 18353267.001).
  • [ISSN] 1473-3099
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


51. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G: High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood; 2009 Aug 13;114(7):1306-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.
  • After the introduction of highly active antiretroviral therapy (HAART), intensive treatment, including high-dose therapy (HDT) and peripheral blood stem cell transplantation (PBSCT), has become feasible in HIV-positive patients with Hodgkin (HL) and non-Hodgkin (NHL) lymphoma.
  • Herein, we report the long-term results, on an intention-to-treat basis, of a prospective study on HDT and PBSCT in 50 HIV-positive HAART-responding patients with refractory/relapsed lymphoma.
  • After debulking therapy, 2 patients had early toxic deaths, 10 had chemoresistant disease, 6 failed stem cell mobilization, 1 refused collection, and 4 progressed soon after PBSC harvest.
  • Twenty-one patients are alive and disease-free after a median follow-up of 44 months (OS, 74.6%; PFS, 75.9%).
  • Only lymphoma response significantly affected OS after transplantation.
  • In multivariate analyses both lymphoma stage and low CD4 count negatively influenced the possibility to receive transplant.
  • PBSCT is a highly effective salvage treatment for chemosensitive AIDS-related lymphoma.
  • It seems rational to explore its use earlier during the course of lymphoma to increase the proportion of patients who can actually receive transplant.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / therapy. Antiretroviral Therapy, Highly Active. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy. Male. Middle Aged. Salvage Therapy / methods. Survival Rate. Transplantation, Autologous


52. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, Falk PM, Rosenthal J, Alvarnas J, Forman SJ: Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood; 2005 Jan 15;105(2):874-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas.
  • The treatment of HIV-associated lymphoma has changed since the widespread use of highly active antiretroviral therapy.
  • HIV-infected individuals can tolerate more intensive chemotherapy, as they have better hematologic reserves and fewer infections.
  • This has led to higher response rates in patients with HIV-associated Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) treated with chemotherapy in conjunction with antiretroviral therapy.
  • However, for patients with refractory or relapsed disease, salvage chemotherapy still offers little chance of long-term survival.
  • In the non-HIV setting, patients with relapsed Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) have a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue (ASCT) compared with conventional salvage chemotherapy.
  • In a prior report we demonstrated that this approach is well tolerated in patients with underlying immunodeficiency from HIV infection.
  • Furthermore, similar engraftment to the non-HIV setting and low infectious risks have been observed.
  • With long-term follow-up we demonstrate that ASCT can lead to an 85% progression-free survival, which suggests that this approach may be potentially curative in select patients with relapsed HIV-associated HD or NHL.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. CD4 Lymphocyte Count. Child. Disease-Free Survival. Follow-Up Studies. Humans. Middle Aged. Recurrence. Remission Induction. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15388574.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI38592; United States / NCI NIH HHS / CA / CA30206; United States / NCI NIH HHS / CA / CA33572
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


53. Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillerm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sureda A, European Group for Blood and Marrow Transplantation Lymphoma Working Party: Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood; 2009 Jun 4;113(23):6011-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation.
  • Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on highly active antiretroviral therapy.
  • We report the first comparative analysis between HIV-Ly and a matched cohort of HIV(-) lymphoma patients.
  • This retrospective European Group for Blood and Marrow Transplantation study included 53 patients (66% non-Hodgkin and 34% Hodgkin lymphoma) within each cohort.
  • Both groups were comparable except for the higher proportion of males, mixed-cellularity Hodgkin lymphoma and patients receiving granulocyte colony-stimulating factor before engraftment and a smaller proportion receiving total body irradiation-based conditioning within the HIV-Ly cohort.
  • A higher nonrelapse mortality within the first year after ASCT was observed in the HIV-Ly group (8% vs 2%), predominantly because of early bacterial infections, although this was not statistically significant and did not influence survival.
  • Thus, within the highly active antiretroviral therapy era, HIV patients should be considered for ASCT according to the same criteria adopted for HIV(-) lymphoma patients.
  • [MeSH-major] HIV Infections / surgery. Hodgkin Disease / surgery. Peripheral Blood Stem Cell Transplantation


54. Wong KH, Lee SS, Chan KC: Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong. Hong Kong Med J; 2006 Apr;12(2):133-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty years of clinical human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in Hong Kong.
  • OBJECTIVE: To elucidate the development of human immunodeficiency virus (HIV) clinical care and research in Hong Kong.
  • DATA SOURCES: Articles on clinical HIV and acquired immunodeficiency syndrome (AIDS) published from 1985 to 2004 were identified through four sources: Red Ribbon Centre, Special Preventive Programme, Secretariat of the Scientific Committee on AIDS, and PubMed search.
  • STUDY SELECTION: Key words for the literature search were 'AIDS', 'HIV', and 'Hong Kong'.
  • The contents were catalogued under seven areas: clinical epidemiology, HIV disease course and presentation, specific complications or organ-based manifestations, immunological evaluation and other monitoring, antiretroviral therapy, HIV/AIDS mortality, and HIV in specific groups.
  • Prevalence of HIV has remained low in Hong Kong but new infections continue to occur together with a significant number of late presenters.
  • Three published AIDS patients' series, up to the first 200 reported cases, identified Pneumocystis carinii pneumonia as the most common AIDS-defining illness in Hong Kong.
  • Local studies of Kaposi's sarcoma and HIV-associated lymphoma have also been reported.
  • Research on CD4 counts has revealed that it is lower in healthy and HIV-infected Chinese than their western counterparts.
  • Children, pregnant women, and haemophiliac patients infected with HIV are among the specific groups of patients studied.
  • Survival of patients with advanced disease has greatly improved over the years, particularly after the advent of highly active antiretroviral therapy.
  • CONCLUSION: The clinical presentation and outcome of HIV/AIDS patients in Hong Kong are a mixture of those of western and developing countries.
  • Research on clinical HIV/AIDS in Hong Kong is not only beneficial to the planning of patient care, but also enables the formulation of treatment guidelines and provides a reference for other countries.


55. Huang T, Shenoy PJ, Sinha R, Graiser M, Bumpers KW, Flowers CR: Development of the Lymphoma Enterprise Architecture Database: a caBIG Silver level compliant system. Cancer Inform; 2009 Apr 03;8:45-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of the Lymphoma Enterprise Architecture Database: a caBIG Silver level compliant system.
  • Lymphomas are the fifth most common cancer in United States with numerous histological subtypes.
  • Integrating existing clinical information on lymphoma patients provides a platform for understanding biological variability in presentation and treatment response and aids development of novel therapies.
  • We developed a cancer Biomedical Informatics Grid (caBIG) Silver level compliant lymphoma database, called the Lymphoma Enterprise Architecture Data-system (LEAD), which integrates the pathology, pharmacy, laboratory, cancer registry, clinical trials, and clinical data from institutional databases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2099-107 [19021052.001]
  • [Cites] J Am Med Inform Assoc. 2008 Jul-Aug;15(4):559-68 [18436897.001]
  • [Cites] BMC Med Inform Decis Mak. 2006;6:25 [16787533.001]
  • [Cites] BMC Med Inform Decis Mak. 2006;6:2 [16398930.001]
  • [Cites] Sci Am. 2001 Jun;284(6):34-5 [11396337.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1099-103 [16151403.001]
  • [Cites] Science. 2005 May 6;308(5723):821-4 [15879210.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2404-12 [14668224.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • (PMID = 19492074.001).
  • [ISSN] 1176-9351
  • [Journal-full-title] Cancer informatics
  • [ISO-abbreviation] Cancer Inform
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2675136
  • [Keywords] NOTNLM ; biomedical informatics grid / caCORE SDK / large linked database / non-Hodgkin’s lymphoma / semantic integration
  •  go-up   go-down


56. Sasco AJ, Jaquet A, Boidin E, Ekouevi DK, Thouillot F, Lemabec T, Forstin MA, Renaudier P, N'dom P, Malvy D, Dabis F: The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One; 2010;5(1):e8621
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenge of AIDS-related malignancies in sub-Saharan Africa.
  • BACKGROUND: With the lengthening of life expectancy among HIV-positive subjects related to the use of highly active antiretroviral treatments, an increased risk of cancer has been described in industrialized countries.
  • The question is to determine what occurs now and will happen in the future in the low income countries and particularly in sub-Saharan Africa where more than two-thirds of all HIV-positive people live in the world.
  • The objective of our paper is to review the link between HIV and cancer in sub-Saharan Africa, putting it in perspective with what is already known in Western countries.
  • METHODS AND FINDINGS: Studies for this review were identified from several bibliographical databases including Pubmed, Scopus, Cochrane, Pascal, Web of Science and using keywords "HIV, neoplasia, epidemiology and Africa" and related MesH terms.
  • A clear association was found between HIV infection and AIDS-classifying cancers.
  • In case-referent studies, odds ratios (OR) were ranging from 21.9 (95% Confidence Interval (CI) 12.5-38.6) to 47.1 (31.9-69.8) for Kaposi sarcoma and from 5.0 (2.7-9.5) to 12.6 (2.2-54.4) for non Hodgkin lymphoma.
  • For non AIDS-classifying cancers, squamous cell conjunctival carcinoma of the eye was associated with HIV in many case-referent studies with ORs from 2.6 (1.4-4.9) to 13.0 (4.5-39.4).
  • A record-linkage study conducted in Uganda showed an association between Hodgkin lymphoma and HIV infection with a standardized incidence ratio of 5.7 (1.2-17) although OR in case-referent studies ranged from 1.4 (0.7-2.8) to 1.6 (1.0-2.7).
  • Other cancer sites found positively associated with HIV include lung, liver, anus, penis, vulva, kidney, thyroid and uterus and a decreased risk of female breast cancer.
  • CONCLUSION: Studies conducted in sub-Saharan Africa show that HIV infection is not only strongly associated with AIDS-classifying cancers but also provided some evidence of association for other neoplasia.
  • African countries need now to implement well designed population-based studies in order to better describe the spectrum of AIDS-associated malignancies and the most effective strategies for their prevention, screening and treatment.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1995 Aug;21 Suppl 1:S121-4 [8547501.001]
  • [Cites] AIDS. 1996 Apr;10(4):413-7 [8728046.001]
  • [Cites] Br J Ophthalmol. 1996 Jun;80(6):503-8 [8759259.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):587-91 [8774574.001]
  • [Cites] Tumori. 1995 Sep-Oct;81(5):308-14 [8804445.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1996;67:1-424 [9190379.001]
  • [Cites] Lancet. 1997 Nov 15;350(9089):1425-31 [9371165.001]
  • [Cites] Am J Clin Nutr. 2004 Nov;80(5):1106-22 [15531656.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):37-42 [9709301.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1521-8 [9836488.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] Int J Gynaecol Obstet. 1999 May;65(2):171-81 [10405062.001]
  • [Cites] Sex Transm Infect. 1999 Apr;75(2):103-6 [10448362.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):659-61 [11295098.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1188-201 [11423251.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):194-7 [11437924.001]
  • [Cites] Int J Gynaecol Obstet. 2002 Jan;76(1):55-63 [11818095.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1921-6 [12493258.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] Sex Transm Dis. 2003 Feb;30(2):137-42 [12567172.001]
  • [Cites] J Womens Health (Larchmt). 2003 Apr;12(3):227-32 [12804353.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Apr;19(2):269-76 [15778115.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5224-8 [16051964.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Rev Med Interne. 2006 Mar;27(3):227-35 [16337065.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):914-9 [16565210.001]
  • [Cites] BMC Cancer. 2006;6:135 [16719902.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):355-62 [16832413.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]
  • [Cites] Cancer Lett. 2006 Nov 28;244(1):1-7 [16542773.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Transplant Proc. 2006 Dec;38(10):3533-5 [17175324.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] J Viral Hepat. 2007 Mar;14(3):183-8 [17305884.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):407.e1-8; discussion 407.e8-9 [17403438.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1480-3 [17437020.001]
  • [Cites] Gynecol Obstet Invest. 2007;63(4):222-8 [17191009.001]
  • [Cites] J Med Virol. 2007 Jun;79(6):758-65 [17457908.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):147-53 [17992576.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2260-5 [18241034.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] J Med Virol. 2008 May;80(5):847-55 [18360898.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Lancet. 2008 May 3;371(9623):1504 [18456099.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2583-8 [10630528.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] J Natl Med Assoc. 2000 Jun;92(6):301-5 [10918766.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2401-8 [9635533.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Bull Cancer. 2003 May;90(5):387-92 [12850760.001]
  • [Cites] J Infect Dis. 2003 Aug 15;188(4):555-63 [12898443.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Int J STD AIDS. 2003 Oct;14(10):647-51 [14596765.001]
  • [Cites] Hepatology. 2004 Jan;39(1):211-9 [14752840.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):638-45 [14760378.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Lancet. 1982 May 1;1(8279):1026-7 [6122840.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Aug 14;36 Suppl 1:1S-15S [3039334.001]
  • [Cites] Lancet. 1990 Jul 7;336(8706):51-2 [1973230.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Ann Intern Med. 1992 Aug 15;117(4):309-11 [1637026.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):695-6 [7885126.001]
  • [Cites] AIDS. 1995 Jan;9(1):57-63 [7893442.001]
  • [Cites] Lancet. 1995 May 27;345(8961):1378-9 [7752795.001]
  • [Cites] Int J Cancer. 1995 Sep 27;63(1):29-36 [7558448.001]
  • (PMID = 20066157.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069919
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2799672
  •  go-up   go-down


57. Krishnan A, Forman SJ: Hematopoietic stem cell transplantation for AIDS-related malignancies. Curr Opin Oncol; 2010 Sep;22(5):456-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for AIDS-related malignancies.
  • PURPOSE OF REVIEW: AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection.
  • In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies.
  • Prior to the advent of effective HIV therapy, stem cell transplantation was not feasible for HIV-positive patients.
  • The purpose of this article is to explore the transplant options for HIV-positive patients after widespread use of highly active antiretroviral therapy.
  • RECENT FINDINGS: Early autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDS patients.
  • Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions.
  • In addition, case-control studies of HIV-positive versus HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival.
  • The feasibility of allogeneic stem cell transplantation in HIV-infected individuals is less tested.
  • SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):284-7 [12140307.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Blood. 1989 Apr;73(5):1340-50 [2649174.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1195-7 [8971396.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3484-7 [18698002.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • (PMID = 20639760.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS427480; NLM/ PMC3537514
  •  go-up   go-down


58. Fellner MD, Durand K, Correa RM, Redini L, Yampolsky C, Colobraro A, Sevlever G, Teyssié AR, Benetucci J, Picconi MA: Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis; 2007 Mar;11(2):172-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma.
  • OBJECTIVE: To analyze Epstein-Barr virus (EBV) load at different HIV infection stages and its relation with brain lymphoma.
  • DESIGN: A cross-sectional study was conducted on 172 HIV-infected individuals: 62 asymptomatic HIV carriers (group A), 30 HIV progressors (group B), 73 AIDS patients (group C), seven AIDS patients with brain lymphoma (group C-BL); and 26 blood donors (group BD) as healthy carriers.
  • RESULTS: PBMC-EBV levels in HIV-infected patients were higher than in the blood donors (p<0.05).
  • Similar PBMC-EBV loads were seen in HIV-infected patients with CD4+ T cell counts higher than 50/mm(3) (p>0.05), while significantly lower levels were found in cases with less than 50 cells/mm(3) (p<0.05).
  • In all HIV-infected patients, plasma-EBV load was lower than, or similar to, PBMC-EBV load, unlike 2/7 HIV-positive brain lymphoma patients.
  • CONCLUSIONS: During HIV infection PBMC-EBV load rises in comparison to healthy carriers, but decreases when immunosuppression progresses and CD4+ T cell count becomes <50/mm(3).
  • Circulating EBV is mainly cell-associated in the HIV-infected population.
  • Neither PBMC-EBV nor plasma-EBV loads would be useful to diagnose brain lymphoma in AIDS patients.
  • [MeSH-major] Brain Neoplasms / virology. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931088.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


59. Miles SA, McGratten M: Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol; 2005 Jan 1;23(1):247-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
  • [MeSH-major] Agammaglobulinemia / chemically induced. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625386.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


60. Noy A: Controversies in the treatment of Burkitt lymphoma in AIDS. Curr Opin Oncol; 2010 Sep;22(5):443-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the treatment of Burkitt lymphoma in AIDS.
  • PURPOSE OF REVIEW: The success of combined antiretroviral therapy (cART) has transformed HIV infection into a survivable chronic disease in developed countries.
  • Increasingly then, the risks of HIV associated cancers become paramount.
  • Burkitt lymphoma is one of the cancer subtypes highly disproportionately affecting HIV infected patients.
  • RECENT FINDINGS: Recent conference proceedings appear to corroborate early reports that intensive therapy of HIV-Burkitt lymphoma is feasible and effective.
  • Moreover, as breakthroughs in the pathogenesis of lymphoma in general and Burkitt lymphoma in particular suggest that HIV infection plays a significant role, the opportunity for targeted therapy based on differences in biology are wholly untapped.
  • SUMMARY: Advances are being made in HIV-Burkitt lymphoma, but future studies need to incorporate our expanding understanding of biology to improve efficacy and reduce toxicity, preferably by integrating a biologic approach to this curable disease.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1492-9 [11920506.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1196-205 [12973843.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):475-8 [14617009.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):667-76 [14770420.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Med Clin North Am. 1992 Jan;76(1):253-68 [1727539.001]
  • [Cites] Am J Clin Pathol. 1995 May;103(5):561-7 [7741100.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):33-9; discussion 45-8 [9578060.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1755-66 [18596745.001]
  • [Cites] Leukemia. 2009 Apr;23(4):807-10 [18987659.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):462-8 [19620863.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Aug;9(4):307-10 [19717381.001]
  • [Cites] Swiss Med Wkly. 2009 Oct 3;139(39-40):564-70 [19838874.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Jan;53(1):124-30 [19730109.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):245-55 [19832807.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1732-9 [19810101.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3008-16 [20023215.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3017-24 [20130244.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • (PMID = 20683266.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA121947-03S4; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / U01 CA121947-03S4
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Other-IDs] NLM/ NIHMS237420; NLM/ PMC3415038
  •  go-up   go-down


61. Wagner-Johnston ND, Ambinder RF: Blood and marrow transplant for lymphoma patients with HIV/AIDS. Curr Opin Oncol; 2008 Mar;20(2):201-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood and marrow transplant for lymphoma patients with HIV/AIDS.
  • PURPOSE OF REVIEW: Important strides in the management of patients with HIV/AIDS-related lymphomas have been made in recent years.
  • This review will discuss the role of bone marrow or peripheral stem-cell transplantation as a modality for patients with HIV and lymphoma.
  • RECENT FINDINGS: In the era of highly active antiretroviral therapy, patients with HIV-associated lymphoma are generally being treated with standard or only slightly modified chemotherapy regimens.
  • Autologous bone marrow and stem-cell transplant approaches in lymphoma patients have been successful.
  • Case reports suggest that allogeneic transplantation for patients with HIV and hematologic malignancies merits further investigation.
  • [MeSH-major] Bone Marrow Transplantation. HIV Infections / complications. HIV Infections / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / therapy. Lymphoma, Non-Hodgkin / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):289-90 [10969356.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2002 Jan 15;99(2):698-701 [11781257.001]
  • [Cites] Exp Hematol. 2002 Mar;30(3):279-84 [11882366.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4423-7 [14581441.001]
  • [Cites] Haematologica. 2004 Sep;89(9):1100-8 [15377471.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2943-6 [15238428.001]
  • [Cites] J Clin Oncol. 1987 Sep;5(9):1322-8 [2442321.001]
  • [Cites] Ann Intern Med. 1989 Dec 15;111(12):973-81 [2512828.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4299-306 [9192752.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1891-7 [15550484.001]
  • [Cites] Exp Hematol. 2005 Apr;33(4):487-94 [15781340.001]
  • [Cites] Bone Marrow Transplant. 2005 Aug;36(3):261-2 [15908966.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Acta Haematol. 2005;114(4):188-97 [16269858.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1560-8 [16502436.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Haematologica. 2007 Feb;92(2):191-8 [17296568.001]
  • [Cites] Haematologica. 2007 Apr;92(4):e56-8 [17562594.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):416-21 [11744828.001]
  • (PMID = 18300771.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA096888; United States / NCI NIH HHS / CA / R01 CA095423
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  • [Other-IDs] NLM/ NIHMS281898; NLM/ PMC4138614
  •  go-up   go-down


62. Latta S, Myint ZW, Jallad B, Hamdi T, Alhosaini MN, Kumar DV, Kheir F: Primary central nervous system T-cell lymphoma in aids patients: case report and literature review. Curr Oncol; 2010 Oct;17(5):63-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system T-cell lymphoma in aids patients: case report and literature review.
  • According to the published data, most primary central nervous system lymphomas (PCNSLs) are B-cell lymphomas; primary T-cell lymphomas are rare.
  • Here, we present the case of a 43-year-old man with AIDS, not on highly active antiretroviral therapy, who presented with focal neurologic symptoms and was found on magnetic resonance imaging to have multiple brain lesions.
  • A biopsy showed T-cell lymphoma, and the patient was subsequently treated with whole-brain radiation, to marked clinical response.
  • Reported cases from the literature of primary T-cell PCNSL in AIDS patients are summarized in this review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20975881.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2949374
  • [Keywords] NOTNLM ; Primary cns lymphoma / T cells / aids / non-Hodgkin lymphoma
  •  go-up   go-down


63. Dupéré-Minier G, Desharnais P, Bernier J: Involvement of tyrosine phosphatase CD45 in apoptosis. Apoptosis; 2010 Jan;15(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, it is involved in apoptosis induced by HIV-1.
  • CD45 defect is implicated in various diseases such as severe-combined immunodeficiency disease (SCID), acquired immunodeficiency syndrome (AIDS), lymphoma and multiple myelomas.
  • The understanding of the mechanisms by which CD45 regulates apoptosis would be very useful in disease treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856105.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


64. Stevenson GT: CD38 as a therapeutic target. Mol Med; 2006 Nov-Dec;12(11-12):345-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferations.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Cell Line, Tumor. Humans. Leukemia / immunology. Lymphoma, B-Cell / immunology. Mice. Mice, SCID. Multiple Myeloma / immunology. Transplantation, Heterologous

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2001 Jan;25(1):1-12 [11137554.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):345-52 [15026555.001]
  • [Cites] Scand J Immunol. 1978 Apr;7(4):297-306 [418499.001]
  • [Cites] Am J Hematol. 1990 Feb;33(2):101-9 [2301368.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1071-9 [1995092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):352-6 [8380497.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1442-9 [7520771.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3017-25 [7524764.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):455-63 [16920192.001]
  • (PMID = 17380203.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.2.2.5 / Antigens, CD38
  • [Other-IDs] NLM/ PMC1829201
  •  go-up   go-down


65. Dawson MA, Schwarer AP, McLean C, Oei P, Campbell LJ, Wright E, Shortt J, Street AM: AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haematologica; 2007 Jan;92(1):e11-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.
  • Plasmablastic lymphoma is an AIDS related lymphoma that continues to have a poor prognosis despite significant advances in the management of HIV and lymphoproliferative diseases.
  • In part this has been due to limited insights into the biology of this disease and the molecular mechanisms of oncogenesis.
  • To date molecular abnormalities have not been described in plasmablastic lymphoma, and its aggressive clinical behaviour has been difficult to understand.
  • We describe the first reported cytogenetic abnormality in plasmablastic lymphoma, an IgH/MYC translocation.
  • [MeSH-major] Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 8 / ultrastructure. Genes, myc. Gingival Neoplasms / genetics. Hemophilia A / complications. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Large-Cell, Immunoblastic / genetics. Peripheral Blood Stem Cell Transplantation. Translocation, Genetic


66. Tulpule A: Multidrug resistance in AIDS-related lymphoma. Curr Opin Oncol; 2005 Sep;17(5):466-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance in AIDS-related lymphoma.
  • PURPOSE OF REVIEW: AIDS-related lymphoma has a decreased response rate and poorer prognosis to standard chemotherapy when compared with lymphoma in the non-HIV population.
  • In addition to the known HIV-related and lymphoma-related poor prognostic factors, this review discusses another factor, MDR-1 expression and its impact on response to therapy in patients with AIDS-related lymphoma.
  • RECENT FINDINGS: There is an increased incidence of de-novo MDR-1 expression in AIDS-related lymphoma compared with lymphoma in the non-HIV settings.
  • MDR-1 expression in AIDS-related lymphoma is associated with poor response to conventional combination chemotherapy.
  • Liposomal encapsulation of doxorubicin when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) seems to overcome P-glycoprotein-mediated drug resistance in AIDS-related lymphoma.
  • SUMMARY: The overexpression of MDR-1 gene product P-glycoprotein is an adverse prognostic factor in AIDS-related lymphoma.
  • Treatment with liposomal encapsulated doxorubicin seems to overcome the P-glycoprotein-related drug resistance.
  • This and other strategies to modulate MDR-1 should be further explored in order to improve success rates in the treatment of AIDS-related lymphoma.
  • [MeSH-major] Drug Resistance, Multiple, Viral / genetics. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / genetics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093797.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 23
  •  go-up   go-down


67. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ, Center for International Blood and Marrow Research, National Marrow Donor program, European Blood and MarrowTransplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Disease Canada, Centers for Disease Control and Prevention: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant; 2009 Oct;15(10):1143-238
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Infection. Infection Control / methods
  • [MeSH-minor] Humans. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Infection Control.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):457-60 [17589532.001]
  • [Cites] Transplantation. 2007 Aug 15;84(3):323-30 [17700156.001]
  • [Cites] Clin Infect Dis. 2007 Sep 15;45(6):673-81 [17712749.001]
  • [Cites] Clin Infect Dis. 2007 Sep 15;45(6):682-6 [17712750.001]
  • [Cites] Am J Infect Control. 2007 Sep;35(7):489-91 [17765565.001]
  • [Cites] Clin Infect Dis. 2007 Oct 1;45(7):846-52 [17806048.001]
  • [Cites] Mayo Clin Proc. 2007 Sep;82(9):1052-9 [17803871.001]
  • [Cites] Med Mycol. 2005 Dec;43(8):705-10 [16422300.001]
  • [Cites] Haematologica. 2006 Jan;91(1):78-83 [16434374.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Feb;50(2):774-7 [16436743.001]
  • [Cites] J Clin Microbiol. 2006 Feb;44(2):395-9 [16455890.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1688-95 [16131570.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1800-5 [16282339.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Mar 3;55(8):209-10 [16511443.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):344-9 [16520475.001]
  • [Cites] Eur J Haematol. 2006 Apr;76(4):342-7 [16519707.001]
  • [Cites] Epidemiol Infect. 2007 Jan;135(1):34-9 [16780608.001]
  • [Cites] Bone Marrow Transplant. 2006 Dec;38(12):813-9 [17057724.001]
  • [Cites] Bone Marrow Transplant. 2006 Dec;38(12):799-805 [17075568.001]
  • [Cites] MMWR Recomm Rep. 2006 Dec 1;55(RR-15):1-48 [17136024.001]
  • [Cites] Appl Environ Microbiol. 2006 Dec;72(12):7602-6 [17056679.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4288-90 [16946302.001]
  • [Cites] Herpes. 2006 Nov;13(3):60-5 [17147908.001]
  • [Cites] Leukemia. 2007 Jan;21(1):12-7 [17109028.001]
  • [Cites] Clin Infect Dis. 2007 Jan 15;44(2):159-77 [17173212.001]
  • [Cites] Clin Infect Dis. 2007 Jan 15;44(2):245-9 [17173225.001]
  • [Cites] Transfusion. 2006 Dec;46(12):2071-82 [17176318.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2725-32 [17192537.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(2):101-7 [17143300.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(2):121-5 [17173054.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2007 Jan;26(1):67-71 [17203286.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):1-25 [17222748.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):74-81 [17222755.001]
  • [Cites] Transplantation. 2004 Nov 15;78(9):1407-8 [15548984.001]
  • [Cites] J Occup Environ Hyg. 2004 Sep;1(9):607-12 [15559332.001]
  • [Cites] MMWR Recomm Rep. 2000 May 9;49(RR-5):1-22; quiz CE1-7 [15580728.001]
  • [Cites] MMWR Recomm Rep. 2000 Mar 31;49(RR-2):59-68 [15580732.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2590-8 [15602019.001]
  • [Cites] Clin Infect Dis. 2005 Jan 1;40(1):67-78 [15614694.001]
  • [Cites] Clin Microbiol Rev. 2005 Jan;18(1):217-45 [15653828.001]
  • [Cites] J Clin Virol. 2005 Feb;32(2):173-8 [15653422.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Oct;11(10):797-804 [16182180.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):709-13 [16062173.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):741-3 [16113670.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 Oct 14;54(40):1021-3 [16224451.001]
  • [Cites] Bone Marrow Transplant. 2005 Nov;36(10):879-83 [16151423.001]
  • [Cites] Haematologica. 2005 Nov;90(11):1582-4 [16266910.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59(9):511-6 [16274955.001]
  • [Cites] J Pak Med Assoc. 2005 Sep;55(9):378-81 [16302471.001]
  • [Cites] J Infect Dis. 2006 Jan 1;193(1):68-79 [16323134.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2442-9 [16322602.001]
  • [Cites] MMWR Recomm Rep. 2005 Dec 16;54(RR-15):1-47 [16357823.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):13-24 [16371015.001]
  • [Cites] Bone Marrow Transplant. 2005 Dec;36(11):1001-8 [16184180.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2005 Dec;24(12):832-8 [16331335.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jan;28(1):23-8 [16394888.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):11-22 [16394298.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1):84-94 [16399572.001]
  • [Cites] Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S114-S117 [18724282.001]
  • [Cites] Transpl Infect Dis. 2008 Jul;10(4):252-9 [18194371.001]
  • [Cites] Infect Control Hosp Epidemiol. 2008 Sep;29(9):866-70 [18681813.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1766-77 [18946062.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5684-8 [18955453.001]
  • [Cites] Ann Hematol. 2009 Mar;88(3):267-72 [18679683.001]
  • [Cites] Bone Marrow Transplant. 2009 Feb;43(3):237-44 [18806838.001]
  • [Cites] J Infect. 2007 Feb;54(2):e83-6 [16806484.001]
  • [Cites] N Engl J Med. 2007 Jan 25;356(4):335-47 [17251530.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):585-9 [15866767.001]
  • [Cites] J Hosp Infect. 2005 Jun;60(2):144-9 [15866013.001]
  • [Cites] J Lab Clin Med. 2005 Mar;145(3):156-62 [15871308.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(11):1065-9 [15806119.001]
  • [Cites] Int J Hematol. 2005 May;81(4):349-51 [15914368.001]
  • [Cites] N Engl J Med. 2005 Jun 2;352(22):2271-84 [15930418.001]
  • [Cites] Transfusion. 2005 Jun;45(6):874-8 [15934984.001]
  • [Cites] Intern Med J. 2005 Jan;35(1):50-5 [15667469.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Feb;11(2):136-48 [15682075.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):503-9 [15686459.001]
  • [Cites] Transplant Proc. 2004 Dec;36(10):3203-7 [15686729.001]
  • [Cites] J Hosp Infect. 2005 Mar;59(3):188-96 [15694975.001]
  • [Cites] Am J Transplant. 2005 Mar;5(3):614-20 [15707418.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):528-37 [15712075.001]
  • [Cites] Curr Hematol Rep. 2005 Mar;4(2):126-31 [15720961.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(5):497-9 [15640812.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):768-76 [15728809.001]
  • [Cites] Infect Control Hosp Epidemiol. 2005 Feb;26(2):161-5 [15756887.001]
  • [Cites] Transpl Infect Dis. 2004 Dec;6(4):142-6 [15762931.001]
  • [Cites] Transpl Infect Dis. 2004 Dec;6(4):171-8 [15762935.001]
  • [Cites] Vox Sang. 2005 Apr;88(3):200-1 [15787731.001]
  • [Cites] Pediatrics. 2005 Apr;115(4):852-60 [15805355.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):737-46 [15750612.001]
  • [Cites] Haematologica. 2005 Apr;90(4):526-33 [15820949.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):932-40 [15824982.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):930-9 [15776111.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):937-9 [15848580.001]
  • [Cites] Antivir Ther. 2005;10(2):225-9 [15865216.001]
  • [Cites] Blood. 2005 Jul 15;106(2):464-9 [15797991.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 6;97(13):1008-11 [15998954.001]
  • [Cites] Pediatr Infect Dis J. 2005 Jul;24(7):648-50 [15999012.001]
  • [Cites] Lancet. 2005 Jul 16-22;366(9481):225-33 [16023513.001]
  • [Cites] Clin Infect Dis. 2005 Aug 15;41(4):435-40 [16028149.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):193-200 [16041209.001]
  • [Cites] Am J Infect Control. 2005 Aug;33(6):320-5 [16061137.001]
  • [Cites] Am J Infect Control. 2005 Aug;33(6):360-7 [16061143.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):123-9 [15908978.001]
  • [Cites] J Exp Med. 2005 Aug 1;202(3):379-86 [16061727.001]
  • [Cites] J Clin Microbiol. 2005 Aug;43(8):3890-4 [16081927.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):595-603 [16098075.001]
  • [Cites] Vox Sang. 2005 Aug;89(2):77-80 [16101687.001]
  • [Cites] Pediatrics. 2005 Sep;116(3):587-94 [16140697.001]
  • [Cites] N Engl J Med. 2005 Sep 8;353(10):977-87 [16148283.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1290-2 [16154862.001]
  • [Cites] J Clin Virol. 2005 Oct;34(2):129-32 [16157264.001]
  • [Cites] Curr Opin Infect Dis. 2007 Aug;20(4):408-11 [17609601.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1307-12 [17613758.001]
  • [Cites] Neurology. 2007 Jul 10;69(2):156-65 [17620548.001]
  • [Cites] MMWR Recomm Rep. 2007 Jul 13;56(RR-6):1-54 [17625497.001]
  • [Cites] Drug Resist Updat. 2007 Jun;10(3):121-30 [17569573.001]
  • [Cites] Clin Microbiol Infect. 2007 Jul;13(7):657-64 [17633390.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD005590 [17636808.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):391-3 [17572716.001]
  • [Cites] Transpl Infect Dis. 2007 Sep;9(3):175-81 [17511825.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):451-6 [17589527.001]
  • [Cites] Infect Control Hosp Epidemiol. 1995 Dec;16(12):680-5 [8683085.001]
  • [Cites] Infect Control Hosp Epidemiol. 1996 Mar;17(3):170-2 [8708356.001]
  • [Cites] Arch Intern Med. 1996 Jul 8;156(13):1458-62 [8678715.001]
  • [Cites] Clin Infect Dis. 1996 May;22(5):778-82 [8722930.001]
  • [Cites] Acta Paediatr Jpn. 1996 Jun;38(3):212-7 [8741308.001]
  • [Cites] Lancet. 1996 Aug 17;348(9025):441-3 [8709784.001]
  • [Cites] Infect Dis Clin North Am. 1995 Dec;9(4):987-1003 [8747776.001]
  • [Cites] Infect Control Hosp Epidemiol. 2007 Oct;28(10):1155-61 [17828692.001]
  • [Cites] Eur J Haematol. 2007 Oct;79(4):317-21 [17680814.001]
  • [Cites] Bone Marrow Transplant. 2006 May;37(9):865-71 [16532015.001]
  • [Cites] Bone Marrow Transplant. 2006 May;37(9):851-6 [16532016.001]
  • [Cites] Adv Exp Med Biol. 2006;577:19-45 [16626025.001]
  • [Cites] Virology. 2006 Apr 10;347(2):296-306 [16413592.001]
  • [Cites] J Hosp Infect. 2006 May;63 Suppl 1:S1-44 [16581155.001]
  • [Cites] Infect Control Hosp Epidemiol. 2006 May;27(5):479-83 [16671029.001]
  • [Cites] Blood. 2006 May 15;107(10):4189-93 [16424393.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):375-96 [16545722.001]
  • [Cites] J Hosp Infect. 2006 Apr;62(4):421-6 [16413085.001]
  • [Cites] Bone Marrow Transplant. 2006 Apr;37(7):693-8 [16501590.001]
  • [Cites] Blood. 2006 Apr 1;107(7):3002-8 [16352807.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Apr;50(4):1419-24 [16569860.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1571-4 [16597897.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):887-91 [16611785.001]
  • [Cites] Clin Infect Dis. 2004 Nov 15;39(10):1407-16 [15546073.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1134-40 [16648196.001]
  • [Cites] Br J Haematol. 2006 Jul;134(1):64-76 [16803570.001]
  • [Cites] Clin Infect Dis. 2006 Aug 1;43(3):331-9 [16804849.001]
  • [Cites] Pediatr Infect Dis J. 2006 Jul;25(7):590-5 [16804427.001]
  • [Cites] Bone Marrow Transplant. 2006 Jul;38(2):127-34 [16751782.001]
  • [Cites] MMWR Recomm Rep. 2006 Jul 7;55(RR-9):1-44 [16826161.001]
  • [Cites] Clin Infect Dis. 2006 Aug 15;43(4):474-84 [16838237.001]
  • [Cites] Clin Microbiol Infect. 2006 Aug;12(8):738-44 [16842568.001]
  • [Cites] Bone Marrow Transplant. 2006 Aug;38(3):183-8 [16785868.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Jul 28;55(29):798-800 [16874295.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Aug 1;24(3):441-52 [16886910.001]
  • [Cites] Mayo Clin Proc. 2006 Aug;81(8):1047-53 [16901028.001]
  • [Cites] MMWR Recomm Rep. 2006 Aug 11;55(RR-12):1-13 [16902398.001]
  • [Cites] Blood Rev. 2006 Sep;20(5):267-87 [16781028.001]
  • [Cites] Diagn Microbiol Infect Dis. 2006 Sep;56(1):75-82 [16876375.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] Vox Sang. 2006 Oct;91(3):221-30 [16958834.001]
  • [Cites] Curr Opin Immunol. 2006 Oct;18(5):565-70 [16893632.001]
  • [Cites] Mayo Clin Proc. 2006 Sep;81(9):1159-71 [16970212.001]
  • [Cites] Medicine (Baltimore). 2006 Sep;85(5):278-87 [16974212.001]
  • [Cites] Clin Infect Dis. 2006 Oct 15;43(8):971-8 [16983607.001]
  • [Cites] Sci Total Environ. 2006 Oct 15;370(1):23-8 [16930679.001]
  • [Cites] Dent Clin North Am. 2006 Oct;50(4):659-76, viii [17000279.001]
  • [Cites] Lancet Infect Dis. 2006 Oct;6(10):629-40 [17008172.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1690-700 [16871276.001]
  • [Cites] Int J Hematol. 2006 Oct;84(3):262-7 [17050202.001]
  • [Cites] J Med Virol. 2006 Dec;78(12):1560-3 [17063522.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1096-7 [17084374.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Nov;12(11):1142-9 [17085307.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5207-15 [17114653.001]
  • [Cites] Scand J Infect Dis. 2008;40(5):399-406 [18418801.001]
  • [Cites] Clin Infect Dis. 2008 May 1;46(9):1401-8 [18419443.001]
  • [Cites] J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9 [18419392.001]
  • [Cites] Pediatrics. 2008 May;121(5):e1178-83 [18450861.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):794-5 [18490697.001]
  • [Cites] MMWR Recomm Rep. 2008 May 23;57(RR-3):1-28 [18496505.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):807-16 [18541201.001]
  • [Cites] Clin Infect Dis. 2008 Jun 15;46(12):1813-21 [18462102.001]
  • [Cites] Rev Med Virol. 2008 Jul-Aug;18(4):233-46 [18383425.001]
  • [Cites] MMWR Recomm Rep. 2008 Aug 8;57(RR-7):1-60 [18685555.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3290-3 [11050018.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1307-12 [11073019.001]
  • [Cites] Bone Marrow Transplant. 2000 Nov;26(9):1017-9 [11100283.001]
  • [Cites] Clin Infect Dis. 2001 Jan;32(1):E1-8 [11118397.001]
  • [Cites] Transfus Med Rev. 2001 Jan;15(1):1-20 [11149975.001]
  • [Cites] Blood. 2001 Jan 15;97(2):388-92 [11154213.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1925-32 [11136263.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2009 Mar 20;58(10):256-60 [19300408.001]
  • [Cites] JAMA. 2009 Mar 25;301(12):1231-41 [19318651.001]
  • [Cites] Curr Opin Hematol. 2007 Mar;14(2):145-51 [17255792.001]
  • [Cites] Expert Rev Anti Infect Ther. 2007 Feb;5(1):105-15 [17266458.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Feb 2;56(4):76-9 [17268405.001]
  • [Cites] Clin Infect Dis. 2007 Mar 1;44(5):625-34 [17278051.001]
  • [Cites] Clin Vaccine Immunol. 2007 Feb;14(2):129-33 [17135451.001]
  • [Cites] Clin Infect Dis. 2007 Mar 15;44(6):857-66 [17304461.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):449-51 [17100972.001]
  • [Cites] Infect Control Hosp Epidemiol. 2005 May;26(5):494-500 [15954490.001]
  • [Cites] J Clin Microbiol. 2005 Jun;43(6):2575-80 [15956366.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(1):39-50 [15908981.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1372-82 [15913983.001]
  • [Cites] Ann Intern Med. 2005 Jun 21;142(12 Pt 1):979-95 [15968013.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Jul;11(7):521-9 [15983552.001]
  • [Cites] Clin Infect Dis. 2005 Jul 15;41(2):273-4 [15983934.001]
  • [Cites] Transfusion. 2007 Apr;47(4):636-43 [17381622.001]
  • [Cites] Medicine (Baltimore). 2007 Mar;86(2):69-77 [17435587.001]
  • [Cites] Clin Infect Dis. 2007 May 15;44(10):1307-14 [17443467.001]
  • [Cites] J Med Microbiol. 2007 May;56(Pt 5):699-701 [17446298.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):125-54 [17448953.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):155-70 [17448954.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):189-207 [17448956.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):265-80 [17448961.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):295-310 [17448963.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):311-27 [17448964.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):329-48 [17448965.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 May;13(5):577-83 [17448917.001]
  • [Cites] Vox Sang. 2007 May;92(4):289-96 [17456152.001]
  • [Cites] Semin Respir Crit Care Med. 2007 Apr;28(2):222-42 [17458776.001]
  • [Cites] Transpl Infect Dis. 2007 Jun;9(2):102-7 [17461994.001]
  • [Cites] Transpl Infect Dis. 2007 Jun;9(2):108-13 [17461995.001]
  • [Cites] Pediatr Transplant. 2007 Jun;11(4):414-8 [17493222.001]
  • [Cites] Bone Marrow Transplant. 2007 Jun;39(11):677-86 [17417664.001]
  • [Cites] Respirology. 2007 May;12(3):394-400 [17539844.001]
  • [Cites] J Hosp Infect. 2006 Jul;63(3):246-54 [16713019.001]
  • [Cites] Infect Control Hosp Epidemiol. 2007 Jul;28(7):818-24 [17564984.001]
  • [Cites] J Infect Dis. 2007 Jul 15;196(2):266-70 [17570114.001]
  • [Cites] Am J Infect Control. 2007 Jun;35(5):347-50 [17577484.001]
  • [Cites] Virology. 2007 Aug 15;365(1):125-35 [17467766.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jul;13(7):760-4 [17580253.001]
  • [Cites] Bone Marrow Transplant. 2007 Jul;40(1):19-27 [17468773.001]
  • [Cites] Clin Infect Dis. 2007 Jul 15;45(2):187-93 [17578777.001]
  • [Cites] MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40 [17585291.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):131-45 [17593020.001]
  • [Cites] Clin Infect Dis. 2007 Aug 1;45(3):302-7 [17599306.001]
  • [Cites] Drugs. 2007;67(10):1411-27 [17600390.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2811-4 [7919390.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3229-35 [7949194.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2471-508 [7964965.001]
  • [Cites] Bone Marrow Transplant. 1994 Aug;14(2):241-5 [7994239.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Oct;39(10):2243-7 [8619576.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1995 Nov-Dec;89(6):596-8 [8594665.001]
  • [Cites] Infect Control Hosp Epidemiol. 1995 Nov;16(11):634-7 [8601683.001]
  • [Cites] Leuk Lymphoma. 1995 Apr;17(3-4):245-9 [8580792.001]
  • [Cites] MMWR Recomm Rep. 1996 Apr 26;45(RR-4):1-18 [8602127.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1996 May 31;45(21):437-9 [8618543.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2726-33 [11929759.001]
  • [Cites] Blood. 2002 Apr 15;99(8):3050-6 [11929799.001]
  • [Cites] Transfus Med Rev. 2002 Apr;16(2):131-43 [11941575.001]
  • [Cites] Am J Infect Control. 2002 Apr;30(2):133-8 [11944004.001]
  • [Cites] Transplantation. 2002 Apr 15;73(7):1154-8 [11965050.001]
  • [Cites] Br J Haematol. 2002 May;117(2):444-50 [11972532.001]
  • [Cites] Transfus Med. 2002 Apr;12(2):85-106 [11982962.001]
  • [Cites] Infect Control Hosp Epidemiol. 1996 Jun;17(6):360-4 [8805066.001]
  • [Cites] Bone Marrow Transplant. 1996 Jun;17(6):1051-6 [8807113.001]
  • [Cites] J Hosp Infect. 2007 Sep;67(1):35-41 [17719681.001]
  • [Cites] Ann Intern Med. 2007 Sep 18;147(6):400-11 [17876022.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2757-60 [17579182.001]
  • [Cites] Clin Infect Dis. 2007 Oct 15;45(8):958-65 [17879908.001]
  • [Cites] Clin Infect Dis. 2007 Oct 15;45(8):1019-24 [17879919.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1216-23 [17889359.001]
  • [Cites] Blood. 2007 Oct 15;110(8):3071-7 [17515400.001]
  • [Cites] MMWR Recomm Rep. 2006 May 19;55(RR-7):1-23 [16708058.001]
  • [Cites] Paediatr Nurs. 2006 May;18(4):14-8 [16719036.001]
  • [Cites] Lancet Infect Dis. 2006 Jun;6(6):374-82 [16728323.001]
  • [Cites] Transplantation. 2006 May 27;81(10):1398-404 [16732176.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):508-14 [16750501.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1119-28 [16699530.001]
  • [Cites] Am J Infect Control. 2006 Jun;34(5):301-7 [16765210.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Nov 16;56(45):1191-2 [18004238.001]
  • [Cites] BMJ. 2007 Nov 17;335(7628):1023 [17940319.001]
  • [Cites] Pharmacotherapy. 2007 Dec;27(12):1627-36 [18041883.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4543-51 [17671230.001]
  • [Cites] Am J Infect Control. 2007 Dec;35(10 Suppl 2):S165-93 [18068814.001]
  • [Cites] Am J Infect Control. 2007 Dec;35(10 Suppl 2):S65-164 [18068815.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jan-Feb;40(1):84-90 [17964828.001]
  • [Cites] Ann Rheum Dis. 2008 Jan;67(1):84-90 [17644549.001]
  • [Cites] Dent Clin North Am. 2008 Jan;52(1):79-109, viii-ix [18154866.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Pediatr Infect Dis J. 2008 Jan;27(1):75-7 [18162946.001]
  • [Cites] Clin Infect Dis. 2008 Jan 1;46(1):120-8 [18171227.001]
  • [Cites] Clin Infect Dis. 2008 Jan 15;46(2):201-11 [18171251.001]
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):402-12 [18181739.001]
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):447-50 [18181742.001]
  • [Cites] Int J Antimicrob Agents. 2007 Dec;30(6):551-4 [18029149.001]
  • [Cites] Clin Infect Dis. 2007 Dec 15;45(12):1576-82 [18190318.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(1):19-21 [17934531.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(1):55-62 [17934532.001]
  • [Cites] J Med Virol. 2008 Mar;80(3):441-54 [18205222.001]
  • [Cites] Jpn J Infect Dis. 2008 Jan;61(1):13-7 [18219128.001]
  • [Cites] Pharmacotherapy. 2008 Feb;28(2):281-4 [18225973.001]
  • [Cites] J Chemother. 2007 Dec;19(6):665-9 [18230547.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Mar;14(3):323-34 [18275899.001]
  • [Cites] J Hosp Infect. 2008 Feb;68(2):159-63 [18207605.001]
  • [Cites] Ann Clin Microbiol Antimicrob. 2008;7:1 [18190701.001]
  • [Cites] Clin Microbiol Infect. 2008 Apr;14(4):295-7 [18190576.001]
  • [Cites] J Food Prot. 2008 Feb;71(2):356-64 [18326187.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):473-81 [18176612.001]
  • [Cites] JAMA. 2008 Mar 12;299(10):1149-57 [18334690.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):409-18 [18347349.001]
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(3):299-303 [10967569.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2055-61 [10979947.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2299-303 [10979980.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2000 Sep 1;49(34):777-8 [10987244.001]
  • [Cites] Am J Med. 2000 Mar;108(4):290-5 [11014721.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2703-11 [11023501.001]
  • [Cites] Am J Infect Control. 2000 Oct;28(5):378-80 [11029139.001]
  • [Cites] Clin Infect Dis. 2000 Oct;31(4):881-6 [11049765.001]
  • [Cites] Clin Infect Dis. 2000 Oct;31(4):995-1000 [11049782.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3286-9 [11050017.001]
  • [Cites] Infect Control Hosp Epidemiol. 2003 Jul;24(7):472-6 [12887233.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2003 Aug 8;52(31):735-9 [12904741.001]
  • [Cites] Clin Infect Dis. 1999 Dec;29(6):1494-501 [10585802.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2003 Aug 15;52(32):769-72 [12917583.001]
  • [Cites] J Hosp Infect. 2003 Aug;54(4):300-4 [12919761.001]
  • [Cites] J Infect Dis. 1997 Sep;176(3):782-5 [9291333.001]
  • [Cites] J Infect Dis. 1997 Sep;176(3):815-8 [9291342.001]
  • [Cites] Infect Control Hosp Epidemiol. 2001 Jan;22(1):19-23 [11198017.001]
  • [Cites] Br J Haematol. 2000 Dec;111(3):782-90 [11122138.001]
  • [Cites] Vaccine. 2010 Mar 24;28(15):2730-4 [20117269.001]
  • [Cites] Cytotherapy. 1999;1(6):485-91 [20426549.001]
  • [Cites] Blood. 2010 Sep 9;116(10):1655-62 [20508161.001]
  • [Cites] Biol Blood Marrow Transplant. 2012 Jan;18(1):145-9 [21820392.001]
  • [Cites] J Clin Microbiol. 2007 Jun;45(6):1735-45 [17442797.001]
  • [Cites] J Pediatr (Rio J). 2007 May-Jun;83(3):217-24 [17380232.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2464-72 [17515569.001]
  • [Cites] Br J Haematol. 2007 Feb;136(4):549-64 [17214739.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Feb 23;56(7):141-3 [17318113.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):820-31 [17236223.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):340-54 [17339619.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2322-6 [17090650.001]
  • [Cites] Annu Rev Immunol. 2007;25:139-70 [17129175.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S102-4 [17382018.001]
  • [Cites] J Infect Dis. 1995 Jun;171(6):1545-52 [7769290.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):455-60 [7599572.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):469-73 [7599574.001]
  • [Cites] Pediatr Infect Dis J. 1995 Apr;14(4):319-20 [7603816.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1038-44 [7675046.001]
  • [Cites] MMWR Recomm Rep. 1995 Sep 22;44(RR-12):1-13 [7565541.001]
  • [Cites] Infect Control Hosp Epidemiol. 1995 Aug;16(8):459-77 [7594392.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3598-603 [7579469.001]
  • [Cites] J Infect Dis. 1995 Oct;172(4):939-43 [7561213.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3979-86 [7579369.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):983-7 [7581102.001]
  • [Cites] Bone Marrow Transplant. 1995 Sep;16(3):393-9 [8535312.001]
  • [Cites] Aust Fam Physician. 1995 Nov;24(11):2099 [8579548.001]
  • [Cites] J Clin Microbiol. 1993 May;31(5):1262-7 [8388889.001]
  • [Cites] Bone Marrow Transplant. 1993 May;11(5):403-6 [8504275.001]
  • [Cites] Pediatrics. 1993 Aug;92(2):202-5 [8393172.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1993 Mar-Apr;87(2):173-6 [8337720.001]
  • [Cites] Infect Dis Clin North Am. 1993 Sep;7(3):655-82 [8254165.001]
  • [Cites] Ophthalmology. 1993 Dec;100(12):1835-9; discussion 1839-40 [8259283.001]
  • [Cites] Semin Hematol. 1993 Oct;30(4 Suppl 4):92-101; discussion 102-4 [7905667.001]
  • [Cites] J Med Virol. 1993 Dec;41(4):319-23 [8106867.001]
  • [Cites] J Infect Dis. 1994 Apr;169(4):775-81 [8133091.001]
  • [Cites] Lancet. 1994 Mar 26;343(8900):749-53 [7907729.001]
  • [Cites] N Engl J Med. 1994 Apr 28;330(17):1185-91 [8093146.001]
  • [Cites] Transplantation. 1994 Mar 15;57(5):677-84 [8140632.001]
  • [Cites] Infect Control Hosp Epidemiol. 1994 Apr;15(4 Pt 1):221-3 [8207183.001]
  • [Cites] Infect Control Hosp Epidemiol. 1994 Apr;15(4 Pt 1):231-8 [8207189.001]
  • [Cites] Clin Infect Dis. 1994 Mar;18(3):273-81; quiz 282-4 [8011804.001]
  • [Cites] Clin Infect Dis. 1994 Apr;18(4):547-52 [8038308.001]
  • [Cites] Clin Infect Dis. 1994 Jan;18(1):14-24 [8054433.001]
  • [Cites] Bone Marrow Transplant. 1994 May;13(5):549-57 [8054907.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):780-9 [11850861.001]
  • [Cites] Vox Sang. 2002 Jan;82(1):32-8 [11856465.001]
  • [Cites] Bone Marrow Transplant. 2002 Feb;29(3):263-7 [11859400.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Jan;23(1):41-3 [11868892.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1978-85 [11877269.001]
  • [Cites] Clin Infect Dis. 2002 Apr 1;34(7):909-17 [11880955.001]
  • [Cites] Int J Hyg Environ Health. 2002 Feb;204(5-6):347-51 [11885359.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2324-30 [11895763.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2002 Mar 15;51(10):210-2 [11922190.001]
  • [Cites] J Clin Microbiol. 2002 Apr;40(4):1555-7 [11923396.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1237-9 [10523159.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1336-43 [10536125.001]
  • [Cites] Clin Infect Dis. 1999 Nov;29(5):1268-73 [10524974.001]
  • [Cites] Clin Infect Dis. 1996 Oct;23(4):773-8 [8909843.001]
  • [Cites] Clin Infect Dis. 1996 Oct;23(4):795-805 [8909847.001]
  • [Cites] Blood. 1996 Nov 15;88(10):4063-71 [8916975.001]
  • [Cites] Transplantation. 1996 Nov 15;62(9):1358-60 [8932286.001]
  • [Cites] Arch Intern Med. 2002 May 13;162(9):1037-43 [11996615.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3916-22 [12010789.001]
  • [Cites] Bone Marrow Transplant. 1996 Jun;17(6):1057-9 [8807114.001]
  • [Cites] Transfus Med Rev. 1996 Jul;10(3):161-70 [8809967.001]
  • [Cites] Transfusion. 1996 Sep;36(9):789-93 [8823451.001]
  • [Cites] Clin Infect Dis. 1996 Mar;22(3):521-4 [8852973.001]
  • [Cites] Bone Marrow Transplant. 1996 Aug;18(2):377-82 [8864449.001]
  • [Cites] Bone Marrow Transplant. 1996 Aug;18(2):473-4 [8864468.001]
  • [Cites] Am J Infect Control. 1996 Aug;24(4):313-42 [8870916.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1111:365-76 [17363431.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4):227-33 [17961721.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4):274-7 [17961727.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4):278-85 [17961728.001]
  • [Cites] Br J Haematol. 2007 Nov;139(4):519-31 [17979942.001]
  • [Cites] Eur Respir J. 2007 Nov;30(5):945-50 [17652312.001]
  • [Cites] Can Commun Dis Rep. 2007 Nov 1;33(ACS-10):1-18 [17992725.001]
  • [Cites] J Infect Dis. 2000 Jan;181(1):309-16 [10608780.001]
  • [Cites] Blood. 2000 Feb 1;95(3):807-14 [10648390.001]
  • [Cites] Infect Control Hosp Epidemiol. 2000 Jan;21(1):18-23 [10656349.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):839-45 [10655394.001]
  • [Cites] J Hosp Infect. 2000 Feb;44(2):81-92 [10662557.001]
  • [Cites] Clin Infect Dis. 2000 Feb;30(2):342-8 [10671339.001]
  • [Cites] Ann Trop Med Parasitol. 1999 Jul;93(5):533-5 [10690250.001]
  • [Cites] Infect Control Hosp Epidemiol. 2000 Feb;21(2):80-5 [10697282.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(1):35-43 [10707997.001]
  • [Cites] Transfusion. 2000 Mar;40(3):285-9 [10738027.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1071-2 [10744095.001]
  • [Cites] Pediatrics. 2000 Apr;105(4 Pt 1):738-42 [10742313.001]
  • [Cites] J Clin Microbiol. 2000 Apr;38(4):1536-8 [10747139.001]
  • [Cites] Arch Intern Med. 2000 Apr 10;160(7):1017-21 [10761968.001]
  • [Cites] Lancet. 2000 Apr 8;355(9211):1231-7 [10770306.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):969-73 [10800065.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2000 Apr 14;49(14):297-9 [10825085.001]
  • [Cites] Am J Med. 1997 Mar 17;102(3A):10-8; discussion 25-6 [10868137.001]
  • [Cites] Am J Med. 1997 Mar 17;102(3A):48-52; discussion 53-4 [10868143.001]
  • [Cites] Am J Med. 1997 Mar 17;102(3A):55-60; discussion 75-6 [10868144.001]
  • [Cites] Am J Med. 1997 Mar 17;102(3A):61-70; discussion 75-6 [10868145.001]
  • [Cites] MMWR Recomm Rep. 2000 Jun 9;49(RR-6):1-51 [10881762.001]
  • [Cites] J Hosp Infect. 2000 Jul;45(3):191-7 [10896797.001]
  • [Cites] Hum Gene Ther. 2000 Jul 1;11(10):1453-63 [10910142.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(4):370-4 [10917572.001]
  • [Cites] Clin Infect Dis. 2000 Jul;31(1):136-43 [10913411.001]
  • [Cites] Pediatrics. 2000 Aug;106(2):E18 [10920174.001]
  • [Cites] Am J Infect Control. 2000 Aug;28(4):311-3 [10926709.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):680-9 [10931469.001]
  • [Cites] Infect Control Hosp Epidemiol. 2000 Aug;21(8):516-9